<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- RR Donnelley Xcelerate Instance Document, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version:  6.23.6 -->
<!-- Round: 3 -->
<!-- Creation date: 2016-11-10T05:36:42Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:emis="http://emisphere.com/20160930" xmlns:us-types="http://fasb.org/us-types/2016-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:country="http://xbrl.sec.gov/country/2016-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2016-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:utr="http://www.xbrl.org/2009/utr">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="emis-20160930.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="eol_PE5372----1610-Q0007_STD_0_20060516_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11091862_F06C42A8-DF2C-48E1-8DB6-12D90346D73A_2_3">3.78</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="eol_PE5372----1610-Q0007_STD_0_20140820_0" unitRef="iso4217_USD" decimals="INF" id="id_11091862_76A0B318-E58E-4C9C-9046-E1391674C467_1001_0">20000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE5372----1610-Q0007_STD_0_20140820_0_2033594x2335086" unitRef="iso4217_USD" decimals="INF" id="id_11091862_76A0B318-E58E-4C9C-9046-E1391674C467_3001_2">5000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE5372----1610-Q0007_STD_0_20141104_0_2033594x2335086" unitRef="iso4217_USD" decimals="INF" id="id_11091862_76A0B318-E58E-4C9C-9046-E1391674C467_3002_2">3000000</us-gaap:DebtInstrumentFaceAmount>
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE5372----1610-Q0007_STD_0_20161114_0" unitRef="shares" decimals="INF" id="id_11091862_6E78A933-93B9-40DD-99D6-BFF25EB74C68_2_5">60687478</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE5372----1610-Q0007_STD_0_20150406_0_2033594x2335086" unitRef="iso4217_USD" decimals="INF" id="id_11091862_76A0B318-E58E-4C9C-9046-E1391674C467_3004_2">5000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE5372----1610-Q0007_STD_0_20100608_0_2033594x2118616" unitRef="iso4217_USD" decimals="INF" id="id_11091862_B111426F-A1E7-4640-BA8D-14B9644EDCD4_1002_0">600000</us-gaap:DebtInstrumentFaceAmount>
  <emis:NumberOfWarrantsExercisedByUnrelatedInvestors contextRef="eol_PE5372----1610-Q0007_STD_0_20110712_0_2026703x2239968" unitRef="shares" decimals="-5" id="id_11091862_191DD95B-41F9-43FF-BCDF-56AD8646B3C7_2002_1">200000</emis:NumberOfWarrantsExercisedByUnrelatedInvestors>
  <emis:LineOfCreditFacilityAdditionalBorrowings contextRef="eol_PE5372----1610-Q0007_STD_0_20150701_0_2028497x2033371" unitRef="iso4217_USD" decimals="INF" id="id_11091862_76A0B318-E58E-4C9C-9046-E1391674C467_2005_3">2000000</emis:LineOfCreditFacilityAdditionalBorrowings>
  <emis:NetProceedsOfSecuredLoanAgreement contextRef="eol_PE5372----1610-Q0007_STD_0_20050926_0" unitRef="iso4217_USD" decimals="-5" id="id_11091862_F06C42A8-DF2C-48E1-8DB6-12D90346D73A_1_0">12900000</emis:NetProceedsOfSecuredLoanAgreement>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE5372----1610-Q0007_STD_0_20050926_0_2033594x2118616" unitRef="pure" decimals="INF" id="id_11091862_F06C42A8-DF2C-48E1-8DB6-12D90346D73A_2001_2">0.11</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE5372----1610-Q0007_STD_0_20050926_0_2033594x2118616" unitRef="iso4217_USD" decimals="INF" id="id_11091862_F06C42A8-DF2C-48E1-8DB6-12D90346D73A_2001_1">15000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE5372----1610-Q0007_STD_0_20121017_0_2033594x2169752" unitRef="iso4217_USD" decimals="INF" id="id_11091862_814EA120-3706-476B-A6DF-7AD4BCE88C96_1001_0">1400000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE5372----1610-Q0007_STD_0_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_0D79EF6F-344B-4AD3-ADFC-27ADB3DF6AC0_1002_23">1404000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_1_12">773000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_1_35">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_6617B8DE-3603-43D0-AB38-9609346E11BD_1_4">12735000</us-gaap:DebtInstrumentUnamortizedDiscount>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="pure" decimals="INF" id="id_11091862_8B361D9A-C327-4910-8F26-A0A46F8A854B_2001_2">0.13</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:Cash contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="iso4217_USD" decimals="-5" id="id_11091862_50B62315-BA6A-4431-9FC9-CA288AB918F1_1_0">12900000</us-gaap:Cash>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_4199828F-5801-4C41-8B8D-0F7FA4471184_1001_3">627000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="iso4217_USD" xsi:nil="true" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_1_27" />
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="shares" decimals="INF" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_1_38">60687478</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="shares" decimals="INF" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_1_37">60977210</us-gaap:CommonStockSharesIssued>
  <us-gaap:Assets contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_1_9">8050000</us-gaap:Assets>
  <us-gaap:AccruedVacationCurrent contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_07499033-1BCF-4F45-BB43-E889FCF0A0F1_1_2">57000</us-gaap:AccruedVacationCurrent>
  <us-gaap:AssetsCurrent contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_1_6">8025000</us-gaap:AssetsCurrent>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="shares" decimals="INF" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_1_36">400000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_1_39">406198000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_1_2">7514000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_1_3">232000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:CommonStockValue contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_1_34">610000</us-gaap:CommonStockValue>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_1_23">55616000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_07499033-1BCF-4F45-BB43-E889FCF0A0F1_1_0">431000</us-gaap:AccountsPayableCurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_1_15">629000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_07499033-1BCF-4F45-BB43-E889FCF0A0F1_1_1">285000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_7029635A-1F13-43DD-9DDD-BCEB5A442CDA_1_11">49999000</us-gaap:DerivativeLiabilities>
  <us-gaap:DueToRelatedPartiesCurrent contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_1_14">2545000</us-gaap:DueToRelatedPartiesCurrent>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_D29FE026-1599-4403-9062-97F6F4B06410_1001_5">39730000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_ED03F810-A5B8-495D-B8DD-4B16E8B0DA7F_1_2">129000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_1_30">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="shares" decimals="INF" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_1_31">4000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PrepaidInsurance contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_319246DA-0FA7-4D9C-AAE6-1A5D5853B873_1_0">40000</us-gaap:PrepaidInsurance>
  <us-gaap:NotesPayableRelatedPartiesNoncurrent contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_1_21">57309000</us-gaap:NotesPayableRelatedPartiesNoncurrent>
  <us-gaap:InventoryFinishedGoods contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_AF913B68-93F5-4245-8150-4DA07793B43A_1001_1">85000</us-gaap:InventoryFinishedGoods>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="shares" decimals="INF" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_1_33">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:InventoryNet contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_1_4">85000</us-gaap:InventoryNet>
  <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="iso4217_USD" decimals="INF" id="id_11091862_BD42BFB5-DE59-455A-9872-7437E290BE6A_1002_0">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
  <us-gaap:Liabilities contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_1_26">174259000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_1_44">8050000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_1_20">23138000</us-gaap:LiabilitiesCurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_ED03F810-A5B8-495D-B8DD-4B16E8B0DA7F_1_0">24000</us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear>
  <us-gaap:NotesPayable contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_6617B8DE-3603-43D0-AB38-9609346E11BD_1_5">64309000</us-gaap:NotesPayable>
  <us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_6B6E36B2-CD6F-4169-B7E5-689DE6A3CBE5_1_4">64309000</us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent>
  <us-gaap:PreferredStockValue contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="iso4217_USD" xsi:nil="true" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_1_29" />
  <us-gaap:NotesPayableCurrent contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_1_13">7000000</us-gaap:NotesPayableCurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_ED03F810-A5B8-495D-B8DD-4B16E8B0DA7F_1_1">74000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_1_7">1000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_4199828F-5801-4C41-8B8D-0F7FA4471184_1001_2">628000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:StockholdersEquity contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_1_43">-166209000</us-gaap:StockholdersEquity>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="iso4217_USD" decimals="-5" id="id_11091862_15EBE9C9-8CD6-404A-96F6-0E36F0106F18_2_1">300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:SharesIssued contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="shares" decimals="INF" id="id_11091862_BAD612F3-8D93-4DD1-A4CF-A327C824373A_1001_0">9253876</us-gaap:SharesIssued>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_1_40">-569065000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="shares" decimals="INF" id="id_11091862_BAD612F3-8D93-4DD1-A4CF-A327C824373A_1001_1">3064416</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:TreasuryStockShares contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="shares" decimals="INF" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_1_42">289732</us-gaap:TreasuryStockShares>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_1_5">194000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:TreasuryStockValue contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_1_41">3952000</us-gaap:TreasuryStockValue>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="shares" decimals="INF" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_1_32">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:SecurityDeposit contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_1_8">24000</us-gaap:SecurityDeposit>
  <emis:RelatedPartyTransactionDerivativeLiabilityNoncurrent contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_1_22">38016000</emis:RelatedPartyTransactionDerivativeLiabilityNoncurrent>
  <emis:LiabilitiesRecordedForIndemnificationProvisions contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="iso4217_USD" decimals="INF" id="id_11091862_42BA0B61-4044-4DEC-8FFB-2545ED145ADD_1001_0">0</emis:LiabilitiesRecordedForIndemnificationProvisions>
  <emis:DeferredLeaseLiabilityAndOtherLiabilitiesNonCurrent contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_1_25">7000</emis:DeferredLeaseLiabilityAndOtherLiabilitiesNonCurrent>
  <emis:DerivativeLiabilitiesRelatedPartyCurrent contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_1_18">11983000</emis:DerivativeLiabilitiesRelatedPartyCurrent>
  <emis:MinimumRequiredCashBalanceUnderCondition contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="iso4217_USD" decimals="INF" id="id_11091862_3B2AADE0-0143-4A00-A031-79C8AFDC80E3_1001_1">15000000</emis:MinimumRequiredCashBalanceUnderCondition>
  <emis:MinimumRequiredCashBalance contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="iso4217_USD" decimals="INF" id="id_11091862_50B62315-BA6A-4431-9FC9-CA288AB918F1_1_1">10000000</emis:MinimumRequiredCashBalance>
  <emis:RoyaltyPayableToRelatedPartiesCurrent contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_1_16">208000</emis:RoyaltyPayableToRelatedPartiesCurrent>
  <emis:PrepaidExpensesAndOtherCurrentAssets contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_319246DA-0FA7-4D9C-AAE6-1A5D5853B873_1_2">154000</emis:PrepaidExpensesAndOtherCurrentAssets>
  <emis:RoyaltyPayableToRelatedPartiesNonCurrent contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_1_24">173000</emis:RoyaltyPayableToRelatedPartiesNonCurrent>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2022410x2021995" unitRef="iso4217_USD" decimals="-3" id="id_11091862_C020FD66-DD38-4828-B7B0-190478B019F9_3001_1">10269000</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2022410x2022419" unitRef="iso4217_USD" decimals="-3" id="id_11091862_C020FD66-DD38-4828-B7B0-190478B019F9_3002_1">39730000</us-gaap:DerivativeLiabilities>
  <us-gaap:ConvertibleNotesPayable contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2025588x2290570" unitRef="iso4217_USD" decimals="-5" id="id_11091862_E3391BCE-8AE4-4E40-8F5B-4CC956F26872_1001_0">49700000</us-gaap:ConvertibleNotesPayable>
  <us-gaap:BridgeLoan contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2025588x2290570" unitRef="iso4217_USD" decimals="-5" id="id_11091862_E3391BCE-8AE4-4E40-8F5B-4CC956F26872_1001_3">2300000</us-gaap:BridgeLoan>
  <us-gaap:NotesPayable contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2025588x2290570_2033594x2175516" unitRef="iso4217_USD" decimals="-5" id="id_11091862_E3391BCE-8AE4-4E40-8F5B-4CC956F26872_2001_2">800000</us-gaap:NotesPayable>
  <emis:DerivativeInstrumentsWarrants contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2026703x2068720" unitRef="iso4217_USD" decimals="-3" id="id_11091862_7029635A-1F13-43DD-9DDD-BCEB5A442CDA_1001_4">437000</emis:DerivativeInstrumentsWarrants>
  <emis:DerivativeInstrumentsWarrants contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2026703x2097458" unitRef="iso4217_USD" decimals="-3" id="id_11091862_7029635A-1F13-43DD-9DDD-BCEB5A442CDA_2001_7">1463000</emis:DerivativeInstrumentsWarrants>
  <us-gaap:CommonStocksIncludingAdditionalPaidInCapital contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2026703x2108947" unitRef="iso4217_USD" decimals="-6" id="id_11091862_64D9B9EB-F454-4AB4-A220-CC34112B0ED7_2001_1">10000000</us-gaap:CommonStocksIncludingAdditionalPaidInCapital>
  <us-gaap:SharePrice contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2026703x2108947" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11091862_93C457E5-E443-4587-8859-653E17C5367A_2001_0">0.70</us-gaap:SharePrice>
  <emis:NumberOfWarrantsIssued contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2026703x2108947" unitRef="shares" decimals="INF" id="id_11091862_64D9B9EB-F454-4AB4-A220-CC34112B0ED7_2001_0">865000</emis:NumberOfWarrantsIssued>
  <emis:FairValueAssumptionConversionPrice contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2026703x2108947" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11091862_93C457E5-E443-4587-8859-653E17C5367A_2001_1">0.50</emis:FairValueAssumptionConversionPrice>
  <us-gaap:CommonStocksIncludingAdditionalPaidInCapital contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2026703x2116523" unitRef="iso4217_USD" decimals="-6" id="id_11091862_78245857-6DB9-43BC-B333-9F3727E714FD_1001_0">10000000</us-gaap:CommonStocksIncludingAdditionalPaidInCapital>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2026703x2116523" unitRef="iso4217_USD" decimals="-3" id="id_11091862_7029635A-1F13-43DD-9DDD-BCEB5A442CDA_3001_0">34388000</us-gaap:DerivativeLiabilities>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2026703x2116523" unitRef="iso4217_USD" decimals="-3" id="id_11091862_D29FE026-1599-4403-9062-97F6F4B06410_2001_3">2113000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:SharePrice contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2026703x2116523" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11091862_79F87DD4-E654-41A8-B3DC-AA1B3FDEEFB1_2001_0">0.70</us-gaap:SharePrice>
  <emis:FairValueAssumptionConversionPrice contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2026703x2116523" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11091862_79F87DD4-E654-41A8-B3DC-AA1B3FDEEFB1_2001_1">1.25</emis:FairValueAssumptionConversionPrice>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2026703x2169752" unitRef="iso4217_USD" decimals="-3" id="id_11091862_7029635A-1F13-43DD-9DDD-BCEB5A442CDA_4001_2">3628000</us-gaap:DerivativeLiabilities>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2026703x2169752" unitRef="iso4217_USD" decimals="-3" id="id_11091862_D29FE026-1599-4403-9062-97F6F4B06410_3001_1">143000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:SharePrice contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2026703x2169752" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11091862_5AE60755-3FF9-4D29-93AF-65E82E0A2BE1_2001_0">0.70</us-gaap:SharePrice>
  <emis:FairValueAssumptionConversionPrice contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2026703x2169752" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11091862_5AE60755-3FF9-4D29-93AF-65E82E0A2BE1_2001_1">0.50</emis:FairValueAssumptionConversionPrice>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2026703x2175516" unitRef="iso4217_USD" decimals="-3" id="id_11091862_7029635A-1F13-43DD-9DDD-BCEB5A442CDA_5001_1">1277000</us-gaap:DerivativeLiabilities>
  <us-gaap:SharePrice contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2026703x2175516" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11091862_8969B07E-C46D-45F3-908B-F6C2E13F35D2_2001_0">0.70</us-gaap:SharePrice>
  <emis:FairValueAssumptionConversionPrice contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2026703x2175516" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11091862_8969B07E-C46D-45F3-908B-F6C2E13F35D2_2001_1">0.50</emis:FairValueAssumptionConversionPrice>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2026703x2206022" unitRef="shares" decimals="-6" id="id_11091862_ED19CA3A-F882-44D0-9E3E-AD5B248F976A_1001_0">10000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:SharePrice contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2026703x2206022" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11091862_1B565D30-961F-45EF-860C-A4134428CFAB_2001_0">0.70</us-gaap:SharePrice>
  <emis:FairValueAssumptionConversionPrice contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2026703x2206022" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11091862_1B565D30-961F-45EF-860C-A4134428CFAB_2001_1">0.50</emis:FairValueAssumptionConversionPrice>
  <emis:DerivativeInstrumentsWarrants contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2026703x2217977" unitRef="iso4217_USD" decimals="-3" id="id_11091862_7029635A-1F13-43DD-9DDD-BCEB5A442CDA_6001_3">1812000</emis:DerivativeInstrumentsWarrants>
  <emis:NumberOfWarrantsIssued contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2026703x2239968" unitRef="shares" decimals="-5" id="id_11091862_191DD95B-41F9-43FF-BCDF-56AD8646B3C7_2001_0">2600000</emis:NumberOfWarrantsIssued>
  <emis:DerivativeInstrumentsWarrants contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2026703x2239968" unitRef="iso4217_USD" decimals="-3" id="id_11091862_7029635A-1F13-43DD-9DDD-BCEB5A442CDA_7001_5">1275000</emis:DerivativeInstrumentsWarrants>
  <emis:DerivativeInstrumentsWarrants contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2026703x2291141" unitRef="iso4217_USD" decimals="-3" id="id_11091862_7029635A-1F13-43DD-9DDD-BCEB5A442CDA_8001_10">4859000</emis:DerivativeInstrumentsWarrants>
  <emis:DerivativeInstrumentsWarrants contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2026703x2352344" unitRef="iso4217_USD" decimals="-3" id="id_11091862_7029635A-1F13-43DD-9DDD-BCEB5A442CDA_10001_9">386000</emis:DerivativeInstrumentsWarrants>
  <emis:DerivativeInstrumentsWarrants contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2026703x2364109" unitRef="iso4217_USD" decimals="-3" id="id_11091862_7029635A-1F13-43DD-9DDD-BCEB5A442CDA_11001_6">474000</emis:DerivativeInstrumentsWarrants>
  <us-gaap:SharePrice contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2026789x2039180" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11091862_4D8346E3-44CA-4F59-A3FF-80B8D16AA009_2001_0">0.70</us-gaap:SharePrice>
  <emis:FairValueAssumptionConversionPrice contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2026789x2039180" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11091862_4D8346E3-44CA-4F59-A3FF-80B8D16AA009_2001_1">0.50</emis:FairValueAssumptionConversionPrice>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2027723x2116523" unitRef="pure" decimals="INF" id="id_11091862_02836261-D58A-47B4-ADB3-D1CE86585ED8_2001_1">0.13</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2027723x2116523" unitRef="iso4217_USD" decimals="INF" id="id_11091862_F3204A84-6102-4622-B13F-1423E77D0E6A_2001_2">49700000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2027723x2116523" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11091862_F3204A84-6102-4622-B13F-1423E77D0E6A_2001_0">1.25</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:NotesPayableRelatedPartiesNoncurrent contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2027723x2116523" unitRef="iso4217_USD" decimals="-3" id="id_11091862_6B6E36B2-CD6F-4169-B7E5-689DE6A3CBE5_1001_0">39067000</us-gaap:NotesPayableRelatedPartiesNoncurrent>
  <us-gaap:NotesPayable contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2027723x2116523" unitRef="iso4217_USD" decimals="-3" id="id_11091862_6617B8DE-3603-43D0-AB38-9609346E11BD_1001_0">49650000</us-gaap:NotesPayable>
  <emis:PercentageOfRoyaltyPaidOnNetSalesUnderConditionTwo contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2027749x2037322" unitRef="pure" decimals="3" id="id_11091862_7B32B99A-9B36-4AC1-ACFD-0269AD310592_2001_2">0.025</emis:PercentageOfRoyaltyPaidOnNetSalesUnderConditionTwo>
  <emis:PercentageOfRoyaltyPaidOnNetSales contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2027749x2037322" unitRef="pure" decimals="2" id="id_11091862_7B32B99A-9B36-4AC1-ACFD-0269AD310592_2001_0">0.20</emis:PercentageOfRoyaltyPaidOnNetSales>
  <emis:PercentageOfRoyaltyPaidOnNetSalesUnderConditionOne contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2027749x2037322" unitRef="pure" decimals="2" id="id_11091862_7B32B99A-9B36-4AC1-ACFD-0269AD310592_2001_1">0.05</emis:PercentageOfRoyaltyPaidOnNetSalesUnderConditionOne>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2030037x2023509" unitRef="iso4217_USD" decimals="-3" id="id_11091862_4199828F-5801-4C41-8B8D-0F7FA4471184_2001_0">601000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2030037x2024220" unitRef="iso4217_USD" decimals="-3" id="id_11091862_4199828F-5801-4C41-8B8D-0F7FA4471184_3001_1">27000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:NotesAndLoansPayableCurrent contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2033594x2031470" unitRef="iso4217_USD" decimals="-5" id="id_11091862_A7C548DA-F454-489D-8B93-AF7538DD139E_4003_5">6200000</us-gaap:NotesAndLoansPayableCurrent>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2033594x2169752" unitRef="pure" decimals="INF" id="id_11091862_814EA120-3706-476B-A6DF-7AD4BCE88C96_2002_1">0.13</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2033594x2169752" unitRef="iso4217_USD" decimals="INF" id="id_11091862_92DA53DE-184C-4636-97A6-B8F4943C8289_2001_5">2300000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:NotesPayableRelatedPartiesNoncurrent contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2033594x2169752" unitRef="iso4217_USD" decimals="-3" id="id_11091862_6B6E36B2-CD6F-4169-B7E5-689DE6A3CBE5_2001_2">106000</us-gaap:NotesPayableRelatedPartiesNoncurrent>
  <us-gaap:NotesPayable contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2033594x2169752" unitRef="iso4217_USD" decimals="-3" id="id_11091862_6617B8DE-3603-43D0-AB38-9609346E11BD_2001_2">2258000</us-gaap:NotesPayable>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2033594x2175516" unitRef="pure" decimals="INF" id="id_11091862_B2EFE399-6D8B-46FF-930E-ACD8F62F3C8A_2001_1">0.10</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2033594x2175516" unitRef="iso4217_USD" decimals="INF" id="id_11091862_B2EFE399-6D8B-46FF-930E-ACD8F62F3C8A_2001_5">800000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2033594x2175516" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11091862_B2EFE399-6D8B-46FF-930E-ACD8F62F3C8A_2001_3">0.50</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:NotesAndLoansPayableCurrent contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2033594x2175516" unitRef="iso4217_USD" decimals="-5" id="id_11091862_A7C548DA-F454-489D-8B93-AF7538DD139E_5003_4">800000</us-gaap:NotesAndLoansPayableCurrent>
  <us-gaap:NotesPayableRelatedPartiesNoncurrent contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2033594x2175516" unitRef="iso4217_USD" decimals="-3" id="id_11091862_6B6E36B2-CD6F-4169-B7E5-689DE6A3CBE5_3001_3">794000</us-gaap:NotesPayableRelatedPartiesNoncurrent>
  <us-gaap:NotesPayable contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2033594x2175516" unitRef="iso4217_USD" decimals="-3" id="id_11091862_6617B8DE-3603-43D0-AB38-9609346E11BD_3001_3">794000</us-gaap:NotesPayable>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2033594x2335086" unitRef="iso4217_USD" decimals="INF" id="id_11091862_E15CEC6E-2449-4C5C-8B55-77C82EBE2376_1001_1">24300000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:NotesPayableRelatedPartiesNoncurrent contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2033594x2335086" unitRef="iso4217_USD" decimals="-3" id="id_11091862_6B6E36B2-CD6F-4169-B7E5-689DE6A3CBE5_4001_1">24342000</us-gaap:NotesPayableRelatedPartiesNoncurrent>
  <us-gaap:LoansPayable contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2033594x2335086" unitRef="iso4217_USD" decimals="-5" id="id_11091862_E3391BCE-8AE4-4E40-8F5B-4CC956F26872_3001_1">24300000</us-gaap:LoansPayable>
  <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2033594x2335086" unitRef="iso4217_USD" decimals="INF" id="id_11091862_8B361D9A-C327-4910-8F26-A0A46F8A854B_3001_0">20000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
  <us-gaap:NotesPayable contextRef="eol_PE5372----1610-Q0007_STD_0_20160930_0_2033594x2335086" unitRef="iso4217_USD" decimals="-3" id="id_11091862_6617B8DE-3603-43D0-AB38-9609346E11BD_4001_1">24342000</us-gaap:NotesPayable>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE5372----1610-Q0007_STD_0_20150106_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_0D79EF6F-344B-4AD3-ADFC-27ADB3DF6AC0_2001_22">3683000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="eol_PE5372----1610-Q0007_STD_0_20150106_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_D29FE026-1599-4403-9062-97F6F4B06410_5001_0">24414000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE5372----1610-Q0007_STD_0_20150106_0_2033594x2335086" unitRef="iso4217_USD" decimals="INF" id="id_11091862_76A0B318-E58E-4C9C-9046-E1391674C467_3003_2">5000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DerivativeLiabilitiesCurrent contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_2_19">205000</us-gaap:DerivativeLiabilitiesCurrent>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_2_12">2121000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_2_35">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_6617B8DE-3603-43D0-AB38-9609346E11BD_2_4">11041000</us-gaap:DebtInstrumentUnamortizedDiscount>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_4199828F-5801-4C41-8B8D-0F7FA4471184_1002_3">616000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_2_27" />
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0" unitRef="shares" decimals="INF" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_2_38">60687478</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0" unitRef="shares" decimals="INF" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_2_37">60977210</us-gaap:CommonStockSharesIssued>
  <us-gaap:Assets contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_2_9">15810000</us-gaap:Assets>
  <us-gaap:AccruedVacationCurrent contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_07499033-1BCF-4F45-BB43-E889FCF0A0F1_2_2">55000</us-gaap:AccruedVacationCurrent>
  <us-gaap:AssetsCurrent contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_2_6">15774000</us-gaap:AssetsCurrent>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0" unitRef="shares" decimals="INF" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_2_36">400000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_2_39">405944000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_2_2">12898000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_2_3">455000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:CommonStockValue contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_2_34">610000</us-gaap:CommonStockValue>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_2_23">55616000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_07499033-1BCF-4F45-BB43-E889FCF0A0F1_2_0">1762000</us-gaap:AccountsPayableCurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_2_15">631000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DepositsAssetsCurrent contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_319246DA-0FA7-4D9C-AAE6-1A5D5853B873_2_1">184000</us-gaap:DepositsAssetsCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_07499033-1BCF-4F45-BB43-E889FCF0A0F1_2_1">304000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_7029635A-1F13-43DD-9DDD-BCEB5A442CDA_2_11">47966000</us-gaap:DerivativeLiabilities>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_D29FE026-1599-4403-9062-97F6F4B06410_1002_0">35623000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_2_30">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0" unitRef="shares" decimals="INF" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_2_31">4000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PrepaidInsurance contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_319246DA-0FA7-4D9C-AAE6-1A5D5853B873_2_0">93000</us-gaap:PrepaidInsurance>
  <us-gaap:NotesPayableRelatedPartiesNoncurrent contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_2_21">54172000</us-gaap:NotesPayableRelatedPartiesNoncurrent>
  <us-gaap:InventoryFinishedGoods contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_AF913B68-93F5-4245-8150-4DA07793B43A_1002_1">782000</us-gaap:InventoryFinishedGoods>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0" unitRef="shares" decimals="INF" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_2_33">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:InventoryNet contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_2_4">1340000</us-gaap:InventoryNet>
  <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="INF" id="id_11091862_BD42BFB5-DE59-455A-9872-7437E290BE6A_1001_0">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
  <us-gaap:Liabilities contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_2_26">167728000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_2_44">15810000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_2_20">22855000</us-gaap:LiabilitiesCurrent>
  <us-gaap:NotesPayable contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_6617B8DE-3603-43D0-AB38-9609346E11BD_2_5">61172000</us-gaap:NotesPayable>
  <us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_6B6E36B2-CD6F-4169-B7E5-689DE6A3CBE5_2_4">61172000</us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent>
  <us-gaap:PreferredStockValue contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_2_29" />
  <us-gaap:InventoryRawMaterials contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_AF913B68-93F5-4245-8150-4DA07793B43A_1002_0">558000</us-gaap:InventoryRawMaterials>
  <us-gaap:NotesPayableCurrent contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_2_13">7000000</us-gaap:NotesPayableCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_2_7">12000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_4199828F-5801-4C41-8B8D-0F7FA4471184_1002_2">628000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:StockholdersEquity contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_2_43">-151918000</us-gaap:StockholdersEquity>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_2_40">-554520000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:TreasuryStockShares contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0" unitRef="shares" decimals="INF" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_2_42">289732</us-gaap:TreasuryStockShares>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_2_5">1081000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:TreasuryStockValue contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_2_41">3952000</us-gaap:TreasuryStockValue>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0" unitRef="shares" decimals="INF" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_2_32">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:SecurityDeposit contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_2_8">24000</us-gaap:SecurityDeposit>
  <emis:RelatedPartyTransactionDerivativeLiabilityNoncurrent contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_2_22">35071000</emis:RelatedPartyTransactionDerivativeLiabilityNoncurrent>
  <emis:DeferredLeaseLiabilityAndOtherLiabilitiesNonCurrent contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_2_25">14000</emis:DeferredLeaseLiabilityAndOtherLiabilitiesNonCurrent>
  <emis:DerivativeLiabilitiesRelatedPartyCurrent contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_2_18">12690000</emis:DerivativeLiabilitiesRelatedPartyCurrent>
  <emis:RoyaltyPayableToRelatedPartiesCurrent contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_2EBFBEF7-D903-4A29-B6D8-D9F993C13D58_2_16">208000</emis:RoyaltyPayableToRelatedPartiesCurrent>
  <emis:PrepaidExpensesAndOtherCurrentAssets contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_319246DA-0FA7-4D9C-AAE6-1A5D5853B873_2_2">804000</emis:PrepaidExpensesAndOtherCurrentAssets>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0_2022410x2021995" unitRef="iso4217_USD" decimals="-3" id="id_11091862_C020FD66-DD38-4828-B7B0-190478B019F9_1001_2">12343000</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0_2022410x2022419" unitRef="iso4217_USD" decimals="-3" id="id_11091862_C020FD66-DD38-4828-B7B0-190478B019F9_1002_2">35623000</us-gaap:DerivativeLiabilities>
  <emis:DerivativeInstrumentsWarrants contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0_2026703x2068720" unitRef="iso4217_USD" decimals="-3" id="id_11091862_7029635A-1F13-43DD-9DDD-BCEB5A442CDA_1002_4">552000</emis:DerivativeInstrumentsWarrants>
  <emis:DerivativeInstrumentsWarrants contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0_2026703x2097458" unitRef="iso4217_USD" decimals="-3" id="id_11091862_7029635A-1F13-43DD-9DDD-BCEB5A442CDA_2002_7">1729000</emis:DerivativeInstrumentsWarrants>
  <us-gaap:SharePrice contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0_2026703x2108947" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11091862_93C457E5-E443-4587-8859-653E17C5367A_2002_0">0.68</us-gaap:SharePrice>
  <emis:FairValueAssumptionConversionPrice contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0_2026703x2108947" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11091862_93C457E5-E443-4587-8859-653E17C5367A_2002_1">0.50</emis:FairValueAssumptionConversionPrice>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0_2026703x2116523" unitRef="iso4217_USD" decimals="-3" id="id_11091862_7029635A-1F13-43DD-9DDD-BCEB5A442CDA_3002_0">30823000</us-gaap:DerivativeLiabilities>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0_2026703x2116523" unitRef="iso4217_USD" decimals="-3" id="id_11091862_D29FE026-1599-4403-9062-97F6F4B06410_2002_3">3648000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:SharePrice contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0_2026703x2116523" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11091862_79F87DD4-E654-41A8-B3DC-AA1B3FDEEFB1_2002_0">0.68</us-gaap:SharePrice>
  <emis:FairValueAssumptionConversionPrice contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0_2026703x2116523" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11091862_79F87DD4-E654-41A8-B3DC-AA1B3FDEEFB1_2002_1">1.25</emis:FairValueAssumptionConversionPrice>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0_2026703x2169752" unitRef="iso4217_USD" decimals="-3" id="id_11091862_7029635A-1F13-43DD-9DDD-BCEB5A442CDA_4002_2">3130000</us-gaap:DerivativeLiabilities>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0_2026703x2169752" unitRef="iso4217_USD" decimals="-3" id="id_11091862_D29FE026-1599-4403-9062-97F6F4B06410_3002_1">377000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:SharePrice contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0_2026703x2169752" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11091862_5AE60755-3FF9-4D29-93AF-65E82E0A2BE1_2002_0">0.68</us-gaap:SharePrice>
  <emis:FairValueAssumptionConversionPrice contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0_2026703x2169752" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11091862_5AE60755-3FF9-4D29-93AF-65E82E0A2BE1_2002_1">0.50</emis:FairValueAssumptionConversionPrice>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0_2026703x2175516" unitRef="iso4217_USD" decimals="-3" id="id_11091862_7029635A-1F13-43DD-9DDD-BCEB5A442CDA_5002_1">1118000</us-gaap:DerivativeLiabilities>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0_2026703x2175516" unitRef="iso4217_USD" decimals="-3" id="id_11091862_D29FE026-1599-4403-9062-97F6F4B06410_4002_2">105000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:SharePrice contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0_2026703x2175516" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11091862_8969B07E-C46D-45F3-908B-F6C2E13F35D2_2002_0">0.68</us-gaap:SharePrice>
  <emis:FairValueAssumptionConversionPrice contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0_2026703x2175516" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11091862_8969B07E-C46D-45F3-908B-F6C2E13F35D2_2002_1">0.50</emis:FairValueAssumptionConversionPrice>
  <us-gaap:SharePrice contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0_2026703x2206022" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11091862_1B565D30-961F-45EF-860C-A4134428CFAB_2002_0">0.68</us-gaap:SharePrice>
  <emis:FairValueAssumptionConversionPrice contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0_2026703x2206022" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11091862_1B565D30-961F-45EF-860C-A4134428CFAB_2002_1">0.50</emis:FairValueAssumptionConversionPrice>
  <emis:DerivativeInstrumentsWarrants contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0_2026703x2217977" unitRef="iso4217_USD" decimals="-3" id="id_11091862_7029635A-1F13-43DD-9DDD-BCEB5A442CDA_6002_3">2142000</emis:DerivativeInstrumentsWarrants>
  <emis:DerivativeInstrumentsWarrants contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0_2026703x2239968" unitRef="iso4217_USD" decimals="-3" id="id_11091862_7029635A-1F13-43DD-9DDD-BCEB5A442CDA_7002_5">1507000</emis:DerivativeInstrumentsWarrants>
  <emis:DerivativeInstrumentsWarrants contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0_2026703x2291141" unitRef="iso4217_USD" decimals="-3" id="id_11091862_7029635A-1F13-43DD-9DDD-BCEB5A442CDA_8002_10">5744000</emis:DerivativeInstrumentsWarrants>
  <emis:DerivativeInstrumentsWarrants contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0_2026703x2350711" unitRef="iso4217_USD" decimals="-3" id="id_11091862_7029635A-1F13-43DD-9DDD-BCEB5A442CDA_9002_8">205000</emis:DerivativeInstrumentsWarrants>
  <emis:DerivativeInstrumentsWarrants contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0_2026703x2352344" unitRef="iso4217_USD" decimals="-3" id="id_11091862_7029635A-1F13-43DD-9DDD-BCEB5A442CDA_10002_9">456000</emis:DerivativeInstrumentsWarrants>
  <emis:DerivativeInstrumentsWarrants contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0_2026703x2364109" unitRef="iso4217_USD" decimals="-3" id="id_11091862_7029635A-1F13-43DD-9DDD-BCEB5A442CDA_11002_6">560000</emis:DerivativeInstrumentsWarrants>
  <us-gaap:SharePrice contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0_2026789x2039180" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11091862_4D8346E3-44CA-4F59-A3FF-80B8D16AA009_2002_0">0.68</us-gaap:SharePrice>
  <emis:FairValueAssumptionConversionPrice contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0_2026789x2039180" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11091862_4D8346E3-44CA-4F59-A3FF-80B8D16AA009_2002_1">0.50</emis:FairValueAssumptionConversionPrice>
  <us-gaap:NotesPayableRelatedPartiesNoncurrent contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0_2027723x2116523" unitRef="iso4217_USD" decimals="-3" id="id_11091862_6B6E36B2-CD6F-4169-B7E5-689DE6A3CBE5_1002_0">37450000</us-gaap:NotesPayableRelatedPartiesNoncurrent>
  <us-gaap:NotesPayable contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0_2027723x2116523" unitRef="iso4217_USD" decimals="-3" id="id_11091862_6617B8DE-3603-43D0-AB38-9609346E11BD_1002_0">46542000</us-gaap:NotesPayable>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0_2030037x2023509" unitRef="iso4217_USD" decimals="-3" id="id_11091862_4199828F-5801-4C41-8B8D-0F7FA4471184_2002_0">601000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0_2030037x2024220" unitRef="iso4217_USD" decimals="-3" id="id_11091862_4199828F-5801-4C41-8B8D-0F7FA4471184_3002_1">27000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:NotesPayableRelatedPartiesNoncurrent contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0_2033594x2169752" unitRef="iso4217_USD" decimals="-3" id="id_11091862_6B6E36B2-CD6F-4169-B7E5-689DE6A3CBE5_2002_2">166000</us-gaap:NotesPayableRelatedPartiesNoncurrent>
  <us-gaap:NotesPayable contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0_2033594x2169752" unitRef="iso4217_USD" decimals="-3" id="id_11091862_6617B8DE-3603-43D0-AB38-9609346E11BD_2002_2">2115000</us-gaap:NotesPayable>
  <us-gaap:NotesPayableRelatedPartiesNoncurrent contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0_2033594x2175516" unitRef="iso4217_USD" decimals="-3" id="id_11091862_6B6E36B2-CD6F-4169-B7E5-689DE6A3CBE5_3002_3">755000</us-gaap:NotesPayableRelatedPartiesNoncurrent>
  <us-gaap:NotesPayable contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0_2033594x2175516" unitRef="iso4217_USD" decimals="-3" id="id_11091862_6617B8DE-3603-43D0-AB38-9609346E11BD_3002_3">755000</us-gaap:NotesPayable>
  <us-gaap:NotesPayableRelatedPartiesNoncurrent contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0_2033594x2335086" unitRef="iso4217_USD" decimals="-3" id="id_11091862_6B6E36B2-CD6F-4169-B7E5-689DE6A3CBE5_4002_1">22801000</us-gaap:NotesPayableRelatedPartiesNoncurrent>
  <us-gaap:NotesPayable contextRef="eol_PE5372----1610-Q0007_STD_0_20151231_0_2033594x2335086" unitRef="iso4217_USD" decimals="-3" id="id_11091862_6617B8DE-3603-43D0-AB38-9609346E11BD_4002_1">22801000</us-gaap:NotesPayable>
  <emis:NumberOfBorrowings contextRef="eol_PE5372----1610-Q0007_STD_1_20140820_0" unitRef="Borrowing" decimals="INF" id="id_11091862_76A0B318-E58E-4C9C-9046-E1391674C467_1_1">5</emis:NumberOfBorrowings>
  <us-gaap:RepaymentsOfDebt contextRef="eol_PE5372----1610-Q0007_STD_1_20151126_0_2033594x2031470" unitRef="iso4217_USD" decimals="-5" id="id_11091862_A7C548DA-F454-489D-8B93-AF7538DD139E_2002_2">6200000</us-gaap:RepaymentsOfDebt>
  <us-gaap:RepaymentsOfDebt contextRef="eol_PE5372----1610-Q0007_STD_1_20151126_0_2033594x2175516" unitRef="iso4217_USD" decimals="-5" id="id_11091862_A7C548DA-F454-489D-8B93-AF7538DD139E_3002_1">800000</us-gaap:RepaymentsOfDebt>
  <us-gaap:ProceedsFromCollaborators contextRef="eol_PE5372----1610-Q0007_STD_1_20151026_0" unitRef="iso4217_USD" decimals="-6" id="id_11091862_815AE708-DB41-416F-A536-992357DF5A20_1_0">14000000</us-gaap:ProceedsFromCollaborators>
  <emis:PercentageOfExtraordinaryReceiptsUsedToPayCertainLoansAndNotes contextRef="eol_PE5372----1610-Q0007_STD_1_20151026_0" unitRef="pure" decimals="2" id="id_11091862_9B4243B3-6795-41E1-9248-5A0AEED89DD3_1_0">0.50</emis:PercentageOfExtraordinaryReceiptsUsedToPayCertainLoansAndNotes>
  <us-gaap:ProceedsFromCollaborators contextRef="eol_PE5372----1610-Q0007_STD_1_20151026_0_2036820x2304402" unitRef="iso4217_USD" decimals="-6" id="id_11091862_815AE708-DB41-416F-A536-992357DF5A20_1001_1">5000000</us-gaap:ProceedsFromCollaborators>
  <us-gaap:ProceedsFromCollaborators contextRef="eol_PE5372----1610-Q0007_STD_1_20151026_0_2036820x2391453" unitRef="iso4217_USD" decimals="-6" id="id_11091862_815AE708-DB41-416F-A536-992357DF5A20_2001_2">9000000</us-gaap:ProceedsFromCollaborators>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="eol_PE5372----1610-Q0007_STD_1_20160930_0_2033594x2169752" unitRef="shares" decimals="INF" id="id_11091862_92DA53DE-184C-4636-97A6-B8F4943C8289_1002_6">4515544</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="eol_PE5372----1610-Q0007_STD_1_20160930_0_2033594x2175516" unitRef="shares" decimals="INF" id="id_11091862_B2EFE399-6D8B-46FF-930E-ACD8F62F3C8A_1002_6">1588682</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE5372----1610-Q0007_STD_267_20150930_0" unitRef="shares" decimals="0" id="id_11091862_37AE058B-D22C-4AA0-939A-9CAC5C7BAA0F_4_700003">74132112</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE5372----1610-Q0007_STD_267_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_0D79EF6F-344B-4AD3-ADFC-27ADB3DF6AC0_2_21">-2279000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE5372----1610-Q0007_STD_267_20150930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_4_19">-0.50</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE5372----1610-Q0007_STD_267_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_4_6">4181000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities contextRef="eol_PE5372----1610-Q0007_STD_267_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_0D79EF6F-344B-4AD3-ADFC-27ADB3DF6AC0_2_16">15975000</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
  <us-gaap:DepreciationAndAmortization contextRef="eol_PE5372----1610-Q0007_STD_267_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_4_8">10000</us-gaap:DepreciationAndAmortization>
  <us-gaap:CostOfGoodsSold contextRef="eol_PE5372----1610-Q0007_STD_267_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_4_1">138000</us-gaap:CostOfGoodsSold>
  <us-gaap:DebtConversionOriginalDebtAmount1 contextRef="eol_PE5372----1610-Q0007_STD_267_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_0D79EF6F-344B-4AD3-ADFC-27ADB3DF6AC0_2_25">3928000</us-gaap:DebtConversionOriginalDebtAmount1>
  <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet contextRef="eol_PE5372----1610-Q0007_STD_267_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_4_15">-188000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
  <us-gaap:Revenues contextRef="eol_PE5372----1610-Q0007_STD_267_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_4_0">225000</us-gaap:Revenues>
  <us-gaap:InterestExpenseRelatedParty contextRef="eol_PE5372----1610-Q0007_STD_267_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_4_16">6391000</us-gaap:InterestExpenseRelatedParty>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE5372----1610-Q0007_STD_267_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_4_17">-16354000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE5372----1610-Q0007_STD_267_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_4_12">8000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:GrossProfit contextRef="eol_PE5372----1610-Q0007_STD_267_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_4_3">87000</us-gaap:GrossProfit>
  <us-gaap:OperatingExpenses contextRef="eol_PE5372----1610-Q0007_STD_267_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_4_9">13987000</us-gaap:OperatingExpenses>
  <us-gaap:NetIncomeLoss contextRef="eol_PE5372----1610-Q0007_STD_267_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_4_18">-30254000</us-gaap:NetIncomeLoss>
  <us-gaap:IncreaseDecreaseInDeferredLiabilities contextRef="eol_PE5372----1610-Q0007_STD_267_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_0D79EF6F-344B-4AD3-ADFC-27ADB3DF6AC0_2_15">2000</us-gaap:IncreaseDecreaseInDeferredLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE5372----1610-Q0007_STD_267_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_0D79EF6F-344B-4AD3-ADFC-27ADB3DF6AC0_2_9">305000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE5372----1610-Q0007_STD_267_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_0D79EF6F-344B-4AD3-ADFC-27ADB3DF6AC0_2_11">535000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInInventories contextRef="eol_PE5372----1610-Q0007_STD_267_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_0D79EF6F-344B-4AD3-ADFC-27ADB3DF6AC0_2_10">-14000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE5372----1610-Q0007_STD_267_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_4_10">-13900000</us-gaap:OperatingIncomeLoss>
  <us-gaap:IncreaseDecreaseInRoyaltiesPayable contextRef="eol_PE5372----1610-Q0007_STD_267_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_0D79EF6F-344B-4AD3-ADFC-27ADB3DF6AC0_2_13">121000</us-gaap:IncreaseDecreaseInRoyaltiesPayable>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE5372----1610-Q0007_STD_267_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_0D79EF6F-344B-4AD3-ADFC-27ADB3DF6AC0_2_20">12000000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="eol_PE5372----1610-Q0007_STD_267_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_0D79EF6F-344B-4AD3-ADFC-27ADB3DF6AC0_2_14">-174000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE5372----1610-Q0007_STD_267_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_0D79EF6F-344B-4AD3-ADFC-27ADB3DF6AC0_2_12">382000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE5372----1610-Q0007_STD_267_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_0D79EF6F-344B-4AD3-ADFC-27ADB3DF6AC0_2_17">-14279000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE5372----1610-Q0007_STD_267_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_0D79EF6F-344B-4AD3-ADFC-27ADB3DF6AC0_2_4">-9971000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE5372----1610-Q0007_STD_267_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_4_5">382000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ProceedsFromLoans contextRef="eol_PE5372----1610-Q0007_STD_267_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_0D79EF6F-344B-4AD3-ADFC-27ADB3DF6AC0_2_19">12000000</us-gaap:ProceedsFromLoans>
  <us-gaap:SellingAndMarketingExpense contextRef="eol_PE5372----1610-Q0007_STD_267_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_4_7">9414000</us-gaap:SellingAndMarketingExpense>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE5372----1610-Q0007_STD_267_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_0D79EF6F-344B-4AD3-ADFC-27ADB3DF6AC0_2_7">219000</us-gaap:ShareBasedCompensation>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE5372----1610-Q0007_STD_267_20150930_0" unitRef="shares" decimals="0" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_4_20">60687478</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <emis:IncreaseInDebtDiscountForNewDerivatives contextRef="eol_PE5372----1610-Q0007_STD_267_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_0D79EF6F-344B-4AD3-ADFC-27ADB3DF6AC0_2_26">1945000</emis:IncreaseInDebtDiscountForNewDerivatives>
  <emis:DerivativeGainLossOnDerivativeNetRelatedParty contextRef="eol_PE5372----1610-Q0007_STD_267_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_4_14">-9783000</emis:DerivativeGainLossOnDerivativeNetRelatedParty>
  <emis:NoncashInterestExpense contextRef="eol_PE5372----1610-Q0007_STD_267_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_0D79EF6F-344B-4AD3-ADFC-27ADB3DF6AC0_2_6">6270000</emis:NoncashInterestExpense>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE5372----1610-Q0007_STD_267_20150930_0_2021628x2022619" unitRef="shares" decimals="0" id="id_11091862_37AE058B-D22C-4AA0-939A-9CAC5C7BAA0F_1004_700000">6390750</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE5372----1610-Q0007_STD_267_20150930_0_2021628x2025566" unitRef="shares" decimals="0" id="id_11091862_37AE058B-D22C-4AA0-939A-9CAC5C7BAA0F_2004_700002">40297635</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE5372----1610-Q0007_STD_267_20150930_0_2021628x2039180" unitRef="shares" decimals="0" id="id_11091862_37AE058B-D22C-4AA0-939A-9CAC5C7BAA0F_3004_700001">25008082</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="eol_PE5372----1610-Q0007_STD_267_20150930_0_2026703x2108947" unitRef="iso4217_USD" decimals="-5" id="id_11091862_3BB9028A-D3F1-40A2-97C3-73C4325334EB_4_1">200000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="eol_PE5372----1610-Q0007_STD_267_20150930_0_2026703x2116523" unitRef="iso4217_USD" decimals="-5" id="id_11091862_1077132B-728C-4E28-BBB4-89785F981CDD_1004_0">4000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="eol_PE5372----1610-Q0007_STD_267_20150930_0_2026703x2169752" unitRef="iso4217_USD" decimals="-5" id="id_11091862_D885EB1C-2C37-42C2-82A3-7D63CDB2564C_1004_0">600000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="eol_PE5372----1610-Q0007_STD_267_20150930_0_2026703x2175516" unitRef="iso4217_USD" decimals="-5" id="id_11091862_5719D650-B037-4B9C-B244-C007093509EE_1004_700000">200000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
  <emis:FairValueOfWarrantsIncreased contextRef="eol_PE5372----1610-Q0007_STD_267_20150930_0_2026703x2206022" unitRef="iso4217_USD" decimals="-5" id="id_11091862_0149DF0A-F4B8-4CC9-97F5-74759753791D_1004_1">2300000</emis:FairValueOfWarrantsIncreased>
  <emis:FairValueOfWarrantsDecreased contextRef="eol_PE5372----1610-Q0007_STD_267_20150930_0_2026703x2239968" unitRef="iso4217_USD" decimals="-3" id="id_11091862_CE8724AD-AF00-4BA0-9B47-A14D33B96176_1002_0">29000</emis:FairValueOfWarrantsDecreased>
  <emis:FairValueOfWarrantsIncreased contextRef="eol_PE5372----1610-Q0007_STD_267_20150930_0_2026703x2350711" unitRef="iso4217_USD" decimals="-5" id="id_11091862_2390537A-25F6-4790-9DC9-46689BFF2ABA_1003_1">200000</emis:FairValueOfWarrantsIncreased>
  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="eol_PE5372----1610-Q0007_STD_267_20150930_0_2026789x2039180" unitRef="iso4217_USD" decimals="-5" id="id_11091862_FA0EDE69-0B47-420F-A4A4-436907E12EFC_1004_1">2500000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
  <dei:EntityRegistrantName contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" id="id_11091862_6E78A933-93B9-40DD-99D6-BFF25EB74C68_1_1">EMISPHERE TECHNOLOGIES INC</dei:EntityRegistrantName>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_D29FE026-1599-4403-9062-97F6F4B06410_1_4">1851000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" unitRef="shares" decimals="0" id="id_11091862_37AE058B-D22C-4AA0-939A-9CAC5C7BAA0F_3_600003">77051651</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:DebtInstrumentDescription contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" id="id_11091862_E15CEC6E-2449-4C5C-8B55-77C82EBE2376_1_0">On August 20, 2014, the  Lenders and the Company further amended and restated (i) the Convertible Notes  issued by the Company to certain of the Lenders, (ii) the Bridge Notes issued by  the Company to certain of the Lenders, and (iii) the Reimbursement Notes (and,  together with the Convertible Notes and Bridge Notes, the "MHR Notes")</us-gaap:DebtInstrumentDescription>
  <dei:DocumentType contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" id="id_11091862_B8EA9802-42DB-4DE8-B57A-A7182E6AE84B_1_1">10-Q</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" id="id_11091862_6E78A933-93B9-40DD-99D6-BFF25EB74C68_1_2">0000805326</dei:EntityCentralIndexKey>
  <us-gaap:DebtDisclosureTextBlock contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" id="id_11091862_235B8463-B751-417E-8C40-7195B1524912_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;9. Notes Payable&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Notes payable, related party, net of related discounts, consists of
 the following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="68%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;September&amp;#xA0;30,&amp;#xA0;2016&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(unaudited)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Convertible Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;39,067&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;37,450&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Loan Agreement&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;24,342&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;22,801&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Bridge Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;106&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;166&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Reimbursement Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;794&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;755&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;64,309&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;61,172&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Less: Current portion&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Non-current notes payable, net of related discounts&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;57,309&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;54,172&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;Loan Agreement.&lt;/b&gt;&amp;#xA0;On August&amp;#xA0;20, 2014, the
 Company entered into a series of agreements (the Transaction
 Documents) with MHR Capital Partners Master Account LP, MHR Capital
 Partners (100)&amp;#xA0;LP, MHR Institutional Partners II LP, and MHR
 Institutional Partners IIA LP, (collectively, &amp;#x201C;MHR&amp;#x201D; or
 the &amp;#x201C;Lenders&amp;#x201D;), for a new loan facility (the
 &amp;#x201C;Loan Agreement&amp;#x201D;), an extension of the Company&amp;#x2019;s
 existing obligations under various promissory notes previously
 issued to the Lenders, and for payment by the Company of certain
 royalties to MHR (the &amp;#x201C;Transaction&amp;#x201D;).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The Loan Agreement provides for, among other things, a commitment
 (the &amp;#x201C;Commitment&amp;#x201D;) of the Lenders to loan the Company
 up to $20 million to finance the development, manufacturing,
 marketing and sale of oral Eligen&amp;#xA0;&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;&amp;#xA0;B12 (the &amp;#x201C;B12
 Product&amp;#x201D;). The Company may made five borrowings (each, a
 &amp;#x201C;Borrowing&amp;#x201D;, and collectively, the &amp;#x201C;Loan&amp;#x201D;)
 under the Loan Agreement. The first borrowing under the Loan
 Agreement occurred on August&amp;#xA0;20, 2014, in an original
 principal amount of $5.0 million, the second occurred on
 November&amp;#xA0;4, 2014 in an original principal amount of $3.0
 million, the third occurred on January&amp;#xA0;6, 2015 in an original
 principal amount of $5.0 million, the fourth occurred on
 April&amp;#xA0;6, 2015 in an original principal amount of $5.0 million,
 and the fifth and final borrowing occurred on July&amp;#xA0;1, 2015 in
 an original principal amount of $2.0 million. In addition, as
 described below, if the Company does not have sufficient cash in
 excess of the Minimum Cash Balance, as defined below, to pay any
 Royalties that become due under the Royalty Agreement, as described
 below, such Royalties will be paid as an additional Loan under the
 Loan Agreement by increasing the principal amount outstanding under
 the Loan Agreement (any such Loan, &amp;#x201C;Paid-In-Kind
 Royalties&amp;#x201D;). The &amp;#x201C;Minimum Cash Balance&amp;#x201D; generally
 means cash on hand (plus certain cash expenditures during such
 fiscal year that are unrelated to the B12 Product or related
 products) of at least $10 million (or $15 million, under certain
 circumstances), subject to certain permitted deductions. On
 December&amp;#xA0;31, 2015, the Company had a $12.9 million cash
 balance, greater than the $10 million Minimum Cash Balance as
 defined under the Loan Agreement, therefore $0.2 million Royalties
 payable for 2015 under the Royalty Agreement was due in cash. MHR
 has agreed to extend the date by which we are required to make the
 $0.2 million Royalty payment in cash under the terms of the Royalty
 Agreement until November&amp;#xA0;15, 2016.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Except with respect to Paid-In-Kind Royalties incurred under the
 Loan Agreement after all amounts of principal and interest have
 previously been paid in full, the Loan will mature on the earlier
 of (a)&amp;#xA0;December&amp;#xA0;31, 2019 and, (b)&amp;#xA0;30 days after the
 end of any fiscal year in which the Company&amp;#x2019;s cash (plus
 certain cash expenditures during such fiscal year that are
 unrelated to the B12 Product or related products) as of the end of
 such fiscal year (subject to certain permitted deductions) is more
 than three times the principal amount of the Loan as of the end of
 such fiscal year. Paid-In-Kind Royalties incurred under the Loan
 Agreement after all amounts of principal and interest have
 previously been paid in full mature one year following the date of
 incurrence. The Loan bears interest at a rate of 13%&amp;#xA0;per annum
 (the &amp;#x201C;Interest Rate&amp;#x201D;), compounded monthly, and will be
 payable in kind and in arrears on June&amp;#xA0;30 and December&amp;#xA0;31
 of each year up to and including the maturity date by increasing
 the outstanding principal amount of the Loan by the amount of each
 such interest payment. So long as an event of default under the
 Loan Agreement (an &amp;#x201C;Event of Default&amp;#x201D;) has occurred and
 is continuing, at the election of MHR, interest shall accrue on the
 Loan at a rate equal to 2%&amp;#xA0;per annum above the Interest Rate
 (&amp;#x201C;Default Rate&amp;#x201D;). Interest at the Default Rate shall
 accrue from the initial date of such Event of Default until that
 Event of Default is cured or waived in writing and shall be payable
 upon demand and, if not paid when due, shall itself bear interest
 at the Default Rate. The Loan must be repaid from time to time
 prior to maturity pursuant to (a)&amp;#xA0;a cash sweep of 50% of the
 Company&amp;#x2019;s adjusted consolidated free cash flow, or 75% of the
 Company&amp;#x2019;s adjusted consolidated free cash flow in any year in
 which the adjusted consolidated free cash flow exceeds $50 million,
 to the extent such cash sweep does not cause the Company&amp;#x2019;s
 cash as of the end of such year to be less than the Minimum Cash
 Balance, (b)&amp;#xA0;a cash sweep of 50% of any cash proceeds received
 from any third party in connection with the license, distribution
 or sale of any of the Company&amp;#x2019;s products other than the B12
 Product or related products (the &amp;#x201C;Non-B12 Products&amp;#x201D;),
 subject to the priority described below, and (c)&amp;#xA0;a Royalty
 Match (as described below), to the extent such Royalty Match does
 not cause the Company&amp;#x2019;s cash as of the end of such year to be
 less than the Minimum Cash Balance and subject to the priority
 described below. The Loan Agreement provides for certain
 representations and warranties, conditions precedent to the
 Lenders&amp;#x2019; obligation to lend, affirmative and negative
 covenants of the Company (including, but not limited to, certain
 milestones in the development of its B12 Products) and Events of
 Default.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 In connection with the cash proceeds of $14 million from Novo
 Nordisk in October 2015, the Company was obligated to pre-pay $0.8
 million of the Reimbursement Notes and $6.2 million of the Loans on
 November&amp;#xA0;26, 2015. The creditor under our Loan Agreement and
 Reimbursement Notes has agreed to extend the date by which we are
 required to pre-pay such amounts under the Loan Agreement and
 Reimbursement Notes until November&amp;#xA0;15, 2016. Because the Loan
 Prepayment deadline has not been extended beyond one year from
 September&amp;#xA0;30, 2016, we have classified $0.8 million of the
 Reimbursement Notes and $6.2 million of the Loans as a current
 liability as of September&amp;#xA0;30, 2016 in the accompanying
 condensed balance sheet.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 In connection with the entry into the Loan Agreement, on
 August&amp;#xA0;20, 2014, the Lenders and the Company further amended
 and restated (i)&amp;#xA0;the Convertible Notes issued by the Company
 to certain of the Lenders, (ii)&amp;#xA0;the Bridge Notes issued by the
 Company to certain of the Lenders, and (iii)&amp;#xA0;the Reimbursement
 Notes (and, together with the Convertible Notes and Bridge Notes,
 the &amp;#x201C;MHR Notes&amp;#x201D;). Also, in connection with the entry
 into the Loan Agreement and the amendment and restatement of the
 MHR Notes, Institutional Partners IIA and the Company have amended
 the Pledge and Security Agreement, dated September&amp;#xA0;26, 2005,
 as amended, by and between the Company and Institutional Partners
 IIA to, among other things, secure the Reimbursement Notes and
 payments due under the Loan Agreement with substantially all of the
 Company&amp;#x2019;s assets, and secure the payments due under the
 Royalty Agreement and Paid-In-Kind Royalties due under the Loan
 Agreement with the Company&amp;#x2019;s intellectual property relating
 to the B12 Products and related products. As of September&amp;#xA0;30,
 2016, the principal balance of the Loan was $24.3 million.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;Convertible Notes.&lt;/b&gt;&amp;#xA0;On September&amp;#xA0;26, 2005, we
 received net proceeds of approximately $12.9 million under a $15
 million secured loan agreement (the &amp;#x201C;2005 Loan
 Agreement&amp;#x201D;) executed with MHR. Under the 2005 Loan Agreement,
 MHR requested, and on May&amp;#xA0;16, 2006, we effected, the exchange
 of the loan from MHR for the predecessor of the Convertible Notes,
 which were 11% senior secured convertible notes with substantially
 the same terms as the 2005 Loan Agreement, except that the original
 Convertible Notes were convertible, at the sole discretion of MHR,
 into shares of our common stock at a price per share of $3.78. In
 connection with the original Convertible Notes exchange, the
 Company agreed to appoint a representative of MHR (the &amp;#x201C;MHR
 Nominee&amp;#x201D;) and another person (the &amp;#x201C;Mutual
 Director&amp;#x201D;) to the Board. Further, the Company agreed to
 amend, and in January 2006 did amend, its certificate of
 incorporation to provide for continuity of the MHR Nominee and the
 Mutual Nominee on the Board so long as MHR holds at least 2% of the
 outstanding common stock of the Company. The original Convertible
 Notes were amended and restated on May&amp;#xA0;7, 2013 and as
 described above, amended and restated a second time on
 August&amp;#xA0;20, 2014.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The Convertible Notes now provide for a new maturity date of
 March&amp;#xA0;31, 2022 (subject to acceleration upon the occurrence of
 certain specified events of default, including the failure to meet
 certain sales, performance, and manufacturing milestones specified
 in the Convertible Notes). The interest rate is 13%&amp;#xA0;per annum,
 compounded monthly, which interest will be payable in the form of
 additional Convertible Notes. The Convertible Notes are
 collateralized by a first priority lien in favor of the Lenders on
 substantially all of the Company&amp;#x2019;s assets. After all
 principal and interest under the Loan Agreement and Reimbursement
 Notes are repaid, the remaining Convertible Notes must be redeemed
 from time to time prior to maturity pursuant to a cash sweep of 50%
 of the Company&amp;#x2019;s adjusted consolidated free cash flow (75% of
 the Company&amp;#x2019;s adjusted consolidated free cash flow in any
 year in which the Company&amp;#x2019;s adjusted consolidated free cash
 flow exceeds $50 million) to the extent such cash sweep does not
 cause the Company&amp;#x2019;s cash as of the end of such year to be
 less than the Minimum Cash Balance. The Convertible Notes are
 convertible, at the option of the holders, at a conversion price of
 $1.25 per share of common stock, which conversion price is subject
 to adjustment upon the occurrence of specified events, including
 stock dividends, stock splits, certain fundamental corporate
 transactions, and certain issuances of common stock by the Company.
 The Convertible Notes must also be redeemed from time to time prior
 to maturity pursuant to (a)&amp;#xA0;a cash sweep of 50% of any cash
 proceeds received from any third party in connection with the
 license, distribution or sale of any Non-B12 Product, subject to
 the priority described below and (b)&amp;#xA0;a Royalty Match (as
 described below), to the extent such Royalty Match does not cause
 the Company&amp;#x2019;s cash as of the end of such year to be less than
 the Minimum Cash Balance and subject to the priority described
 below. If we fail to meet our obligations under the terms of the
 Convertible Notes, or fail to meet any of the net sales targets
 included in the Convertible Notes, we would be in default under
 these notes, which would give MHR the option of foreclosing on
 substantially all of our assets. We do not anticipate meeting the
 annual sales target at December&amp;#xA0;31, 2016, however, the Company
 is currently in discussions with the creditor for a permanent
 waiver of this condition. As of September&amp;#xA0;30, 2016, the
 principal balance of the Convertible Notes was $49.7 million; and
 the Convertible Notes were convertible into 39,720,243 shares of
 our common stock.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;Reimbursement Notes.&lt;/b&gt;&amp;#xA0;On June&amp;#xA0;8, 2010, the
 Company issued the predecessor to the Reimbursement Notes to MHR in
 the form of certain non-interest bearing promissory notes in the
 aggregate principal amount of $600,000 in reimbursement for legal
 expenses incurred by MHR in connection with MHR&amp;#x2019;s agreement
 to, among other things, waive certain rights as a senior secured
 party of the Company and enter into a non-disturbance agreement
 with the Company&amp;#x2019;s collaboration partner, Novartis Pharma AG,
 and, if necessary, to enter into a comparable agreement in
 connection with another potential Company transaction. The original
 Reimbursement Notes were amended and restated on May&amp;#xA0;7, 2013
 and, as described above, amended and restated again on
 August&amp;#xA0;20, 2014.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The Reimbursement Notes provide for a maturity date of the earlier
 of (a)&amp;#xA0;March&amp;#xA0;31, 2022 and (b)&amp;#xA0;immediately prior to
 the time that any amounts outstanding under the Loan Agreement are
 repaid (subject to acceleration upon the occurrence of certain
 events of default specified in the Reimbursement Notes), and bear
 interest at the rate of 10%&amp;#xA0;per annum, compounded monthly,
 which interest is payable in the form of additional Reimbursement
 Notes. The Reimbursement Notes are collateralized by a first
 priority lien in favor of the Lenders on substantially all of the
 Company&amp;#x2019;s assets. The Reimbursement Notes are convertible, at
 the option of the holders, at a conversion price of $0.50 per share
 of common stock, which conversion price is subject to adjustment
 upon the occurrence of specified events, including stock dividends,
 stock splits, certain fundamental corporate transactions, and
 certain issuances of common stock by the Company. The Reimbursement
 Notes must also be redeemed from time to time prior to maturity
 pursuant to a cash sweep of 50% of any cash proceeds received from
 any third party in connection with the license, distribution or
 sale of any Non-B12 Product, subject to the priority described
 below. As of September&amp;#xA0;30, 2016, the principal balance of the
 Reimbursement Notes was $0.8 million; and the Reimbursement Notes
 were convertible into 1,588,682 shares of our common stock.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 In connection with the cash proceeds of $14 million from Novo
 Nordisk in October 2015, the Company was obligated to pre-pay $0.8
 million of the Reimbursement Notes and $6.2 million of the Loans on
 November&amp;#xA0;26, 2015. The creditor under the Reimbursement Notes
 and Loan Agreement has agreed to extend the date by which we are
 required to pre-pay such amounts under the Reimbursement Notes and
 Loan Agreement until November&amp;#xA0;15, 2016.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;Bridge Notes.&lt;/b&gt;&amp;#xA0;On October&amp;#xA0;17, 2012, the
 Company issued to MHR the predecessor to the Bridge Notes in the
 aggregate principal amount of $1,400,000. The original Bridge Notes
 provided for an interest rate of 13%&amp;#xA0;per annum and were
 payable on demand. The Bridge Notes were amended and restated on
 May&amp;#xA0;7, 2013 and restated again on August&amp;#xA0;20, 2014.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The Bridge Notes provide for a maturity date of March&amp;#xA0;31, 2022
 (subject to acceleration upon the occurrence of certain events of
 default specified) and bear interest at 13%&amp;#xA0;per year,
 compounded monthly and payable in the form of additional Bridge
 Notes. The Bridge Notes are collateralized by a first priority lien
 in favor of the Lenders on substantially all of the Company&amp;#x2019;s
 assets. The Bridge Notes are convertible, at the option of the
 holders, at a conversion price of $0.50 per share of common stock,
 which conversion price is subject to adjustment upon the occurrence
 of specified events, including stock dividends, stock splits,
 certain fundamental corporate transactions, and certain issuances
 of common stock by the Company. The Bridge Notes must also be
 redeemed from time to time prior to maturity pursuant to (a)&amp;#xA0;a
 cash sweep of 50% of any cash proceeds received from any third
 party in connection with the license, distribution or sale of any
 Non-B12 Product, subject to the priority described below and
 (b)&amp;#xA0;a Royalty Match (as described below), to the extent such
 Royalty Match does not cause the Company&amp;#x2019;s cash as of the end
 of such year to be less than the Minimum Cash Balance and subject
 to the priority described below. As of September&amp;#xA0;30, 2016, the
 principal balance the Bridge Notes was $2.3 million; and the Bridge
 Notes were convertible into 4,515,544 shares of our common
 stock.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The priority of the cash sweep for Non-B12 Products is as follows:
 (i)&amp;#xA0;to redeem the Reimbursement Notes, (ii)&amp;#xA0;to prepay
 principal and interest outstanding under the Loan Agreement;
 (iii)&amp;#xA0;to reduce the Commitment; (iv)&amp;#xA0;to redeem the
 Convertible Notes; and (v)&amp;#xA0;to redeem the Bridge Notes.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;Royalty Agreement&lt;/b&gt;. As a condition to MHR entering into the
 Loan Agreement and amending and restating the MHR Notes, the
 Company and MHR entered into a Royalty Agreement (the
 &amp;#x201C;Royalty Agreement&amp;#x201D;) on August&amp;#xA0;20, 2014 pursuant
 to which the Company agreed to pay to MHR, subject to specified
 terms and conditions, royalties in perpetuity (the
 &amp;#x201C;Royalties&amp;#x201D;), commencing as of the date of the Royalty
 Agreement, in an amount equal to: twenty percent (20%)&amp;#xA0;of all
 Net Product Sales (as defined in the Royalty Agreement) and any
 third party payments arising in connection with the sale of the B12
 Product and related products, during any fiscal year; provided
 that, from and after October&amp;#xA0;1, 2015, if no amount of
 indebtedness is outstanding under the Loan Agreement (the
 &amp;#x201C;Indebtedness Repayment Condition&amp;#x201D;), such amount shall
 be reduced to (i)&amp;#xA0;five percent (5%)&amp;#xA0;of all Net Sales and
 third party payments commencing with the first quarter immediately
 following the quarter in which the Indebtedness Repayment Condition
 is satisfied, or (ii)&amp;#xA0;two and one half percent (2.5%)&amp;#xA0;of
 all Net Sales commencing with the quarter immediately following the
 quarter in which the Indebtedness Repayment Condition is satisfied,
 but only with respect to the Net Sales made in any country in which
 there was not a Valid Patent Claim (as defined in the Royalty
 Agreement) and where generic entry of a competitive product not by
 the Company or its affiliates that does not infringe a Valid Patent
 Claim in such country has occurred, in each case as of the last day
 of such Fiscal Quarter. Once the royalty rate has been reduced to
 5%, the rate shall not be reinstated to 20% even if amounts become
 outstanding under the Loan Agreement as a result of Paid-In-Kind
 Royalties. Payments of Royalties shall be made in cash to the
 extent such Royalties do not cause the Company&amp;#x2019;s cash as of
 the end of any year to be less than the Minimum Cash Balance, and
 otherwise shall be paid as Paid-In-Kind Royalties.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 If any Royalties become due under the Royalty Agreement when the
 royalty rate is 5% or 2.5%, the amount outstanding under the Loan
 Agreement, Convertible Notes and Bridge Notes shall be reduced in
 an amount equal to such royalty payment, to the extent such payment
 does not cause the Company&amp;#x2019;s cash as of the end of such year
 to be less than the Minimum Cash Balance (the &amp;#x201C;Royalty
 Match&amp;#x201D;), in the following priority: (i)&amp;#xA0;first, to prepay
 the Loan; (ii)&amp;#xA0;second, to redeem the Convertible Notes; and
 (iii)&amp;#xA0;finally, to redeem the Bridge Notes. For the three and
 nine months ended September&amp;#xA0;30, 2016, the Company recorded $32
 and $173 thousand of royalty expense, respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The carrying value of the MHR Notes is comprised of the
 following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="68%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;September&amp;#xA0;30,&amp;#xA0;2016&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(unaudited)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Convertible Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;49,650&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;46,542&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Loan Agreement&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;24,342&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;22,801&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Bridge Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,258&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,115&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Reimbursement Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;794&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;755&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Unamortized discounts&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(12,735&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(11,041&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;64,309&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;61,172&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;br class="Apple-interchange-newline" /&gt;

 &lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
  <dei:DocumentPeriodEndDate contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" id="id_11091862_B8EA9802-42DB-4DE8-B57A-A7182E6AE84B_1_3">2016-09-30</dei:DocumentPeriodEndDate>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_0D79EF6F-344B-4AD3-ADFC-27ADB3DF6AC0_1_21">-5384000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_3_19">-0.24</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_15EBE9C9-8CD6-404A-96F6-0E36F0106F18_1_0">254000</us-gaap:AllocatedShareBasedCompensationExpense>
  <dei:DocumentFiscalYearFocus contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" id="id_11091862_B8EA9802-42DB-4DE8-B57A-A7182E6AE84B_1_4">2016</dei:DocumentFiscalYearFocus>
  <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" id="id_11091862_07DEDE14-8E15-4696-88DA-6CE76BEA092B_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The following table summarizes the changes in fair value of the
 Company&amp;#x2019;s Level 3 financial instruments for the periods ended
 September&amp;#xA0;30, 2016 and December&amp;#xA0;31, 2015.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;br /&gt;
 2016&lt;br /&gt;
 (unaudited)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Beginning Balance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;35,623&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;24,414&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Derivative liability of embedded conversion feature of the Bridge
 Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;143&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;377&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Derivative liability of embedded conversion feature of the
 Reimbursement Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;105&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Derivative liability of the embedded conversion feature of the
 Convertible Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,113&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,648&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Change in fair value&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,851&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,079&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Ending Balance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;39,730&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;35,623&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
  <dei:AmendmentFlag contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" id="id_11091862_B8EA9802-42DB-4DE8-B57A-A7182E6AE84B_1_2">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" id="id_11091862_6E78A933-93B9-40DD-99D6-BFF25EB74C68_1_3">--12-31</dei:CurrentFiscalYearEndDate>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_3_6">4043000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_0D79EF6F-344B-4AD3-ADFC-27ADB3DF6AC0_1_16">9161000</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
  <us-gaap:DebtInstrumentIssuanceDate1 contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" id="id_11091862_F06C42A8-DF2C-48E1-8DB6-12D90346D73A_4_4">2006-05-16</us-gaap:DebtInstrumentIssuanceDate1>
  <us-gaap:DepreciationAndAmortization contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_3_8">11000</us-gaap:DepreciationAndAmortization>
  <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" id="id_11091862_A6729AE4-CFDF-4CD6-81EF-3A6429E724A2_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;10. Derivative Instruments&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Derivative instruments consist of the following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&amp;#xA0;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(unaudited)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Convertible Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;34,388&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;30,823&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Reimbursement Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,277&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,118&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Bridge Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,628&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,130&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Amended and Restated August 2009 Warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,812&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,142&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Amended and Restated June 2010 MHR Warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;437&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;552&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Amended and Restated August 2010 Warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,275&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,507&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Amended and Restated August 2010 MHR Waiver Warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;474&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;560&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Amended and Restated July 2011 Warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,463&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,729&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 July 2011 Investor Warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;205&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Amended and Restated July 2011 MHR Waiver Warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;386&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;456&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 May 2013 MHR Modification Warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,859&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,744&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;49,999&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;47,966&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Some of the Company&amp;#x2019;s outstanding derivative instruments have
 an exercise price reset feature. The estimated fair value of
 warrants and embedded conversion features that have an exercise
 price reset feature is estimated using the Monte Carlo valuation
 model. The estimated fair value of warrants that do not contain an
 exercise price reset feature is measured using the Black-Scholes
 valuation model. Inherent in both of these models are assumptions
 related to expected volatility, remaining life, risk-free rate and
 expected dividend yield. For the Monte Carlo model, we estimate the
 probability and timing of potential future financing and
 fundamental transactions as applicable.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;&lt;i&gt;Embedded Conversion Feature of MHR Notes.&lt;/i&gt;&lt;/b&gt; The
 Convertible Notes, the Reimbursement Notes, and the Bridge Notes
 (collectively, the &amp;#x201C;MHR Notes&amp;#x201D;) contain a provision
 whereby the conversion price is adjustable upon the occurrence of
 certain events, including the issuance by Emisphere of common stock
 or common stock equivalents at a price which is lower than the
 current conversion price of each of the MHR Notes and lower than
 the then-current market price. Under FASB ASC 815-40-15-5, the
 embedded conversion feature of the MHR Notes is not considered
 indexed to the Company&amp;#x2019;s own stock and, therefore, does not
 meet the scope exception in FASB ASC 815-10-15 and thus needs to be
 accounted for as a derivative liability. The liabilities associated
 with the Convertible Notes and the Bridge Notes have been presented
 as a non-current liability as of September&amp;#xA0;30, 2016 and
 December&amp;#xA0;31, 2015, to correspond to their host contracts.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 &lt;b&gt;Convertible Notes&lt;/b&gt;&lt;b&gt;&lt;i&gt;.&lt;/i&gt;&lt;/b&gt; In addition to the
 foregoing, the adjustment provision of the Convertible Notes does
 not become effective unless and until the Company were to raise $10
 million through the issuance of common stock or common stock
 equivalents during any consecutive 24 month period. The fair value
 of the embedded conversion feature of the Convertible Notes is
 estimated at the end of each quarterly reporting period using the
 Monte Carlo model. The assumptions used in computing the fair
 values as September&amp;#xA0;30, 2016 and December&amp;#xA0;31, 2015, are
 as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Closing stock price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.70&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.68&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Conversion price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.25&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.25&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;146&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;143&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Remaining term (years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.25&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Risk-free rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.20&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.95&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The fair value of the embedded conversion feature of the
 Convertible Notes increased $0.6 million and $1.5 million for the
 three and nine months ended September&amp;#xA0;30, 2016, respectively,
 which has been recognized in the accompanying statements of
 operations. The fair value of the embedded conversion feature of
 the Convertible Notes decreased $0.3 million and increased $4.0
 million for the three and nine months ended September&amp;#xA0;30,
 2015, respectively, which has been recognized in the accompanying
 statement of operations.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 &lt;b&gt;Reimbursement Notes&lt;/b&gt;&lt;i&gt;.&lt;/i&gt; The fair value of the embedded
 conversion feature of the Reimbursement Notes is estimated at the
 end of each quarterly reporting period using the Monte Carlo model.
 The assumptions used in computing the fair value as of
 September&amp;#xA0;30, 2016 and December&amp;#xA0;31, 2015 are as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Closing stock price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.70&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.68&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Conversion price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;146&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;143&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Remaining term (years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.25&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Risk-free rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.20&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.95&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The fair value of the embedded conversion of the Reimbursement
 Notes increased $35 thousand and $0.2 million for the three and
 nine months ended September&amp;#xA0;30, 2016, respectively, which has
 been recognized in the accompanying statements of operations. The
 fair value of the embedded conversion feature of the Reimbursement
 Notes decreased $33 thousand and increased $0.2 million for the
 three and nine months ended September&amp;#xA0;30, 2015, respectively,
 which has been recognized in the accompanying statement of
 operations.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 &lt;b&gt;Bridge Notes&lt;/b&gt;&lt;i&gt;.&lt;/i&gt; The fair value of the embedded
 conversion feature of the Bridge Notes is estimated at the end of
 each quarterly reporting period using the Monte Carlo model. The
 assumptions used in computing the fair value as of
 September&amp;#xA0;30, 2016 and December&amp;#xA0;31, 2015 are as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;br /&gt;
 2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Closing stock price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.70&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.68&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Conversion price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;146&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;143&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Remaining term (years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.25&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Risk-free rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.20&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.95&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The fair value of the embedded conversion feature of the Bridge
 Notes increased $0.1 million and $0.4 million for the three and
 nine months ended September&amp;#xA0;30, 2016 respectively, which has
 been recognized in the accompanying statements of operations. The
 fair value of the embedded conversion feature of the Bridge Notes
 decreased $0.1 million and increased $0.6 million for the three and
 nine months ended September&amp;#xA0;30, 2015, respectively, which has
 been recognized in the accompanying statements of operations.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;Amended and Restated June 2010 Warrants.&lt;/b&gt; In June 2010, the
 Company granted MHR warrants to purchase 865,000 shares of its
 common stock (the &amp;#x201C;June 2010 Warrants&amp;#x201D;). In connection
 with the Restructuring, on May&amp;#xA0;7, 2013, the Company amended
 and restated the Original Warrants such that the expiration date of
 the Original Warrant was extended to July&amp;#xA0;8, 2019, and the
 exercise price was reduced to $0.50 per share (as amended and
 restated, the &amp;#x201C;Amended and Restated June 2010
 Warrants&amp;#x201D;). The exercise price of the Amended and Restated
 June 2010 Warrants is adjustable upon the occurrence of certain
 events, including the issuance by Emisphere of common stock or
 common stock equivalents at a price which is lower than the current
 exercise price of these warrants and lower than the current market
 price. However, the adjustment provision does not become effective
 unless the Company were to raise $10 million through the issuance
 of common stock or common stock equivalents at a price which is
 lower than the current conversion price of these warrants and lower
 than the current market price during any consecutive 24 month
 period. The fair value of the Amended and Restated June 2010
 Warrants is estimated at the end of each quarterly reporting period
 using the Monte Carlo model. The assumptions used in computing the
 fair value of the Amended and Restated June 2010 Warrants as of
 September&amp;#xA0;30, 2016 and December&amp;#xA0;31, 2015, are as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Closing stock price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.70&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.68&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Conversion price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;107&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;136&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Remaining term (years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.77&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.52&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Risk-free rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.85&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.42&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The fair value of the Amended and Restated June 2010 MHR Warrants
 decreased $15 thousand and $0.1 million for the three and nine
 months ended September&amp;#xA0;30, 2016, respectively, which has been
 recognized in the accompanying statements of operations. The fair
 value of the Amended and Restated June 2010 MHR Warrants decreased
 $60 thousand and increased $0.2 million for the three and nine
 months September&amp;#xA0;30, 2015, respectively, which has been
 recognized in the accompanying statements of operations.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 &lt;b&gt;Amended and Restated Warrants.&lt;/b&gt; Prior to the Restructuring,
 the Company issued to MHR warrants to purchase varying amounts of
 its common stocks at various times from 2009 through 2011, as
 described more fully below (the August 2009 Warrants, August 2010
 Warrants, August 2010 MHR Waiver Warrants, July 2011 Warrants, July
 2011 MHR Waiver Warrants, and collectively, the &amp;#x201C;Original
 Warrants&amp;#x201D;). In connection with the Restructuring, on
 May&amp;#xA0;7, 2013, the Company amended and restated each of the
 Original Warrants such that the expiration date of each Original
 Warrant was extended to July&amp;#xA0;8, 2019, and the exercise price
 was reduced to $0.50 per share (as amended and restated, the
 &amp;#x201C;Amended and Restated August 2009 Warrants&amp;#x201D;,
 &amp;#x201C;Amended and Restated August 2010 Warrants&amp;#x201D;,
 &amp;#x201C;Amended and Restated August 2010 MHR Waiver Warrants&amp;#x201D;,
 &amp;#x201C;Amended and Restated July 2011 Warrants&amp;#x201D;,
 &amp;#x201C;Amended and Restated July 2011 MHR Waiver Warrants&amp;#x201D;,
 and collectively, the &amp;#x201C;Amended and Restated Warrants&amp;#x201D;)
 . Under the terms of each of the Amended and Restated Warrants, as
 well as the August 2010 Investor Warrants, July 2011 Investor
 Warrants and 2013 Restructuring Warrants (collectively, the
 Investor Warrants, and together with the Original Warrants, the
 &amp;#x201C;Warrants&amp;#x201D;), the Company has an obligation to make a
 cash payment to the holders of each of the Warrants for any gain
 that could have been realized if such holder exercised the warrants
 and we subsequently failed to deliver a certificate representing
 the shares to be issued upon such exercise by the third trading day
 after the Warrants were exercised. Accordingly, the Warrants have
 been accounted for as a liability. The fair value of each of the
 Warrants is estimated, at the end of each quarterly reporting
 period, using the Black-Scholes model. The assumptions used in
 computing the fair value of the Original Warrants as of
 September&amp;#xA0;30, 2016 and December&amp;#xA0;31, 2015, are as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Closing stock price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.70&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.68&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Conversion price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;107&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;141&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Remaining term (years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.77&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.52&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Risk-free rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.88&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.31&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The fair value of the Original Warrants decreased $0.2 million and
 $1.0 million for the three and nine months ended September&amp;#xA0;30,
 2016, respectively, which has been recognized in the accompanying
 statements of operations. The fair value of the Original Warrants
 decreased $1.0 million and increased $2.5 million for the three and
 nine months ended September&amp;#xA0;30, 2015, respectively, which has
 been recognized in the accompanying statements of operations.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;2013 Restructuring Warrants&lt;/b&gt;&lt;i&gt;.&lt;/i&gt; The Company issued to
 MHR warrants to purchase 10&amp;#xA0;million shares of its common stock
 (the &amp;#x201C;2013 Restructuring Warrants&amp;#x201D;) as part of the
 Restructuring. The assumptions used in computing the fair value of
 the 2013 Restructuring Warrants as of September&amp;#xA0;30, 2016 and
 December&amp;#xA0;31, 2015, are as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Closing stock price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.70&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.68&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Conversion price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;107&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;141&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Remaining term (years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.77&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.52&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Risk-free rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.88&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.31&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The fair value of the 2013 Restructuring Warrants decreased $0.1
 million and $0.9 million for the three and nine months ended
 September&amp;#xA0;30, 2016, respectively, which has been recognized in
 the accompanying statements of operations. The fair value of the
 2013 Restructuring Warrants decreased $0.9 million and increased
 $2.3 million for the three and nine months ended September&amp;#xA0;30,
 2015, respectively, which has been recognized in the accompanying
 statements of operations.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 &lt;b&gt;August 2010 Investor Warrants&lt;/b&gt;&lt;i&gt;.&lt;/i&gt; In connection with the
 August 2010 Financing, Emisphere sold warrants to purchase
 2.6&amp;#xA0;million shares of common stock to unrelated investors (the
 &amp;#x201C;August 2010 Warrants&amp;#x201D;). On July&amp;#xA0;12, 2011, one of
 the unrelated investors notified the Company of its intention to
 exercise 0.2&amp;#xA0;million warrants. On August&amp;#xA0;26, 2015, the
 remaining 2010 Investor Warrants expired.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The fair value of the August 2010 Investor Warrants decreased $15
 thousand and $29 thousand for the three and nine months ended
 September&amp;#xA0;30, 2015, respectively, which has been recognized in
 the accompanying statements of operations.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 &lt;b&gt;July 2011 Investor Warrants&lt;/b&gt;&lt;i&gt;.&lt;/i&gt; In connection with the
 July 2011 Financing, Emisphere sold warrants to purchase
 3.01&amp;#xA0;million shares of common stock to unrelated investors
 (the &amp;#x201C;July 2011 Warrants&amp;#x201D;). On July&amp;#xA0;6, 2016, the
 July 2011 Warrants expired.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The fair value of the July 2011 Investor Warrants decreased $0.2
 million for the nine months ended September&amp;#xA0;30, 2016, which
 has been recognized in the accompanying statements of operations.
 The July 2011 Investor Warrants decreased $0.2 million and
 increased $0.2 million for the three and nine months ended
 September&amp;#xA0;30, 2015, respectively, which has been recognized in
 the accompanying statements of operations.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
  <us-gaap:DebtInstrumentInterestRateTerms contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" id="id_11091862_2796B579-1B6E-4E17-A7B9-C4E71EF7D169_1_2">Interest at a rate of 13% per annum (the "Interest Rate"), compounded monthly,  and will be payable in kind and in arrears on June 30 and December 31 of each  year</us-gaap:DebtInstrumentInterestRateTerms>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" id="id_11091862_8DD86804-2B78-4577-B101-8F0E3B6FCB1F_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;4. Stock-Based Compensation Plans&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 On April&amp;#xA0;20, 2007, our stockholders approved the 2007 Stock
 Award and Incentive Plan (the &amp;#x201C;2007 Plan&amp;#x201D;). The 2007
 Plan provides for grants of options, stock appreciation rights,
 restricted stock, deferred stock, bonus stock and awards in lieu of
 obligations, dividend equivalents, other stock-based awards and
 performance awards to our executive officers and other employees,
 and non-employee directors, consultants and others who provide
 substantial services to us. The 2007 Plan provides for the issuance
 of an aggregate of 9,253,876 shares. As of September&amp;#xA0;30, 2016,
 3,064,416 shares are available for future grants under our active
 equity plans.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Total compensation expense recorded during the three and nine
 months ended September&amp;#xA0;30, 2016 for share-based payment awards
 was $80&amp;#xA0;thousand and $254 thousand, respectively. At
 September&amp;#xA0;30, 2016, total unrecognized estimated compensation
 expense related to non-vested stock options granted prior to that
 date was $0.3 million which is expected to be recognized over a
 weighted-average period of approximately 1.4 years. No options were
 exercised in the three or nine months ended September&amp;#xA0;30,
 2016. No tax benefit was realized due to a continued pattern of
 operating losses.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 During the nine months ended September&amp;#xA0;30, 2016, the Company
 granted 40,000 options to Michael Garone, former Chief Financial
 Officer (valued on the grant date at $0.61 using the Black Scholes
 pricing model).&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The following weighted-average assumptions were used for grants
 made under the stock option plans for the nine months ended
 September&amp;#xA0;30, 2016:&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="68%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="89%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;145.82&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Expected term (years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.79&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Risk free rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.82&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Annual forfeiture rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14.523&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" unitRef="iso4217_USD" decimals="INF" id="id_11091862_15EBE9C9-8CD6-404A-96F6-0E36F0106F18_1_4">0</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions>
  <dei:DocumentFiscalPeriodFocus contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" id="id_11091862_B8EA9802-42DB-4DE8-B57A-A7182E6AE84B_1_5">Q3</dei:DocumentFiscalPeriodFocus>
  <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" id="id_11091862_7E3916B6-43E2-442D-AAD2-B58CC9A2008C_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Prepaid expenses and other current assets consist of the
 following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="68%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;September&amp;#xA0;30,&amp;#xA0;2016&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(unaudited)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Prepaid corporate insurance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;40&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;93&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Deposit on inventory&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;184&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Prepaid expenses and other current assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;154&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;804&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;194&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,081&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
  <dei:EntityFilerCategory contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" id="id_11091862_6E78A933-93B9-40DD-99D6-BFF25EB74C68_1_4">Smaller Reporting Company</dei:EntityFilerCategory>
  <us-gaap:CostOfGoodsSold contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_3_1">139000</us-gaap:CostOfGoodsSold>
  <us-gaap:DebtConversionOriginalDebtAmount1 contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_0D79EF6F-344B-4AD3-ADFC-27ADB3DF6AC0_1_25">4830000</us-gaap:DebtConversionOriginalDebtAmount1>
  <us-gaap:FairValueDisclosuresTextBlock contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" id="id_11091862_44B4358D-12F0-4027-BA84-CE1ECA80F980_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;15. Fair Value&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 In accordance with FASB ASC 820, &lt;i&gt;&amp;#x201C;Fair Value Measurements
 and Disclosures,&amp;#x201D;&lt;/i&gt; the following table represents the
 Company&amp;#x2019;s fair value hierarchy for its financial assets and
 liabilities measured at fair value on a recurring basis as of
 September&amp;#xA0;30, 2016 and December&amp;#xA0;31, 2015:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="61%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;September&amp;#xA0;30, 2016&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; WIDTH: 66.85pt; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;(unaudited)&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(In&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(In&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(In&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Derivative Instruments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,269&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;39,730&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;49,999&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="16"&gt;&lt;/td&gt;
 &lt;td height="16" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="16" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="16" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; WIDTH: 64.65pt; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;December&amp;#xA0;31, 2015&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;(In
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(In&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(In&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Derivative Instruments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,343&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;35,623&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;47,966&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Level 3 financial instruments consist of certain common stock
 warrants and embedded conversion features. The fair value of these
 warrants and embedded conversion features that have exercise reset
 features are estimated using a Monte Carlo valuation model. The
 unobservable input used by the Company was the estimation of the
 likelihood of a reset occurring on the embedded conversion feature
 of the Amended and Restated Convertible Notes, the embedded
 conversion feature of the Amended and Restated Reimbursement Notes,
 the embedded conversion feature of the Amended and Restated Bridge
 Notes, and the embedded conversion feature of the Amended and
 Restated June 2010 Warrants. These estimates of the likelihood of
 completing an equity raise that would meet the criteria to trigger
 the reset provisions are based on numerous factors, including the
 remaining term of the financial instruments and the Company&amp;#x2019;s
 overall financial condition.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The following table summarizes the changes in fair value of the
 Company&amp;#x2019;s Level 3 financial instruments for the periods ended
 September&amp;#xA0;30, 2016 and December&amp;#xA0;31, 2015.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;br /&gt;
 2016&lt;br /&gt;
 (unaudited)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Beginning Balance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;35,623&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;24,414&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Derivative liability of embedded conversion feature of the Bridge
 Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;143&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;377&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Derivative liability of embedded conversion feature of the
 Reimbursement Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;105&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Derivative liability of the embedded conversion feature of the
 Convertible Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,113&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,648&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Change in fair value&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,851&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,079&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Ending Balance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;39,730&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;35,623&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Changes in the unobservable input values would likely cause
 material changes in the fair value of the Company&amp;#x2019;s Level 3
 financial instruments. The significant unobservable input used in
 the fair value measurement is the estimation of the likelihood of
 the occurrence of a change to the contractual terms of the
 financial instruments. A significant increase (decrease) in this
 likelihood would result in a higher (lower) fair value
 measurement.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" id="id_11091862_9370727C-71E4-475F-8292-DD0C3CB00E0D_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;12. Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;i&gt;Commitments.&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 We lease office space at 4 Becker Farm Road, Roseland, New Jersey
 under a non-cancellable operating lease expiring in 2017.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 As of September&amp;#xA0;30, 2016, future minimum rental payments are
 as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="84%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="13%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; WIDTH: 95.55pt; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;Years Ending December&amp;#xA0;31,&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;(In&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2016 (remaining)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;24&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;74&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;129&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company evaluates the financial consequences of legal actions
 periodically or as facts present themselves and records accruals to
 account for its best estimate of future costs accordingly.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Contingencies.&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 In the ordinary course of business, we enter into agreements with
 third parties that include indemnification provisions which, in our
 judgment, are normal and customary for companies in our industry
 sector. These agreements are typically with business partners,
 clinical sites, and suppliers. Pursuant to these agreements, we
 generally agree to indemnify, hold harmless, and reimburse
 indemnified parties for losses suffered or incurred by the
 indemnified parties with respect to our product candidates, use of
 such product candidates, or other actions taken or omitted by us.
 The maximum potential amount of future payments we could be
 required to make under these indemnification provisions is
 unlimited. We have not incurred material costs to defend lawsuits
 or settle claims related to these indemnification provisions. As a
 result, the estimated fair value of liabilities relating to these
 provisions is minimal. Accordingly, we have no liabilities recorded
 for these provisions as of September&amp;#xA0;30, 2016.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In the normal course of business, we may be confronted with issues
 or events that may result in a contingent liability. These
 generally relate to lawsuits, claims, environmental actions or the
 action of various regulatory agencies. If necessary, management
 consults with counsel and other appropriate experts to assess any
 matters that arise. If, in our opinion, we have incurred a probable
 loss as set forth by accounting principles generally accepted in
 the U.S., an estimate is made of the loss and the appropriate
 accounting entries are reflected in our financial statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 As a condition to MHR entering into the Loan Agreement and amending
 and restating the MHR Notes, the Company and MHR entered into a
 Royalty Agreement (the &amp;#x201C;Royalty Agreement&amp;#x201D;) on
 August&amp;#xA0;20, 2014 providing for the payment by the Company to
 MHR of certain royalties on the terms and conditions set forth
 therein (see Note 9).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Under the terms of the Royalty Agreement, the Company agreed to pay
 to MHR, subject to the terms and conditions of the Royalty
 Agreement, royalties in perpetuity (the &amp;#x201C;Royalties&amp;#x201D;),
 commencing as of the date of the Royalty Agreement, in an amount
 equal to: twenty percent (20%)&amp;#xA0;of all Net Product Sales (as
 defined in the Royalty Agreement) and any third party payments
 arising in connection with the sale of the B12 Product and related
 products, during any fiscal year; provided that, from and after
 October&amp;#xA0;1, 2015, if no amount of indebtedness is outstanding
 under the Loan Agreement (the &amp;#x201C;Indebtedness Repayment
 Condition&amp;#x201D;), such amount shall be reduced to (i)&amp;#xA0;five
 percent (5%)&amp;#xA0;of all Net Sales and third party payments
 commencing with the first quarter immediately following the quarter
 in which the Indebtedness Repayment Condition is satisfied, or
 (ii)&amp;#xA0;two and one half percent (2.5%)&amp;#xA0;of all Net Sales
 commencing with the quarter immediately following the quarter in
 which the Indebtedness Repayment Condition is satisfied, but only
 with respect to the Net Sales made in any country in which there
 was not a Valid Patent Claim (as defined in the Royalty Agreement)
 and where generic entry of a competitive product not by the Company
 or its affiliates that does not infringe a Valid Patent Claim in
 such country has occurred, in each case as of the last day of such
 Fiscal Quarter. Once the royalty rate has been reduced to 5%, the
 rate shall not be reinstated to 20% even if amounts become
 outstanding under the Loan Agreement as a result of Paid-In-Kind
 Royalties. Payments of Royalties shall be made in cash to the
 extent such Royalties do not cause the Company&amp;#x2019;s cash as of
 the end of any year to be less than the Minimum Cash Balance, and
 otherwise shall be paid as Paid-In-Kind Royalties.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:AccountingChangesAndErrorCorrectionsTextBlock contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" id="id_11091862_73A06B79-2776-40EE-8A15-68B77E7E5632_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;14. New Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 In July 2015, the FASB issued ASU
 No.&amp;#xA0;2015-11,&amp;#xA0;&amp;#x201C;Simplifying the Measurement of
 Inventory&amp;#x201D; (&amp;#x201C;ASU 2015-11&amp;#x201D;). ASU 2015-11 requires
 that inventory within the scope of the guidance be measured at the
 lower of cost and net realizable value. Inventory measured using
 last-in, first-out and retail inventory method are excluded from
 this new guidance. This ASU replaces the concept of market with the
 single measurement of net realizable value and is intended to
 create efficiencies for preparers and more closely aligns U.S. GAAP
 with IFRS. This ASU is effective for public business entities in
 fiscal years beginning after December&amp;#xA0;15, 2016, including
 interim periods within those years. Prospective application is
 required and early adoption is permitted as of the beginning of an
 interim or annual reporting period. The Company is currently
 evaluating the impact of the new standards.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 In April&amp;#xA0;2015, the FASB issued ASU 2015-03, &amp;#x201C;Interest
 &amp;#x2013; Imputation of Interest&amp;#x201D; (&amp;#x201C;ASU 2015-03&amp;#x201D;),
 which requires that debt issuance costs related to a recognized
 debt liability be presented in the balance sheet as a direct
 deduction from the carrying amount of that debt liability,
 consistent with debt discounts. The recognition and measurement
 guidance for debt issuance costs are not affected by the amendments
 in this ASU. ASU 2015-03 is effective for annual and interim
 periods beginning on or after December&amp;#xA0;15, 2015. The adoption
 of ASU 2015-03 did not have a material impact on our financial
 position, results of operations or cash flows.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In May 2014, the FASB issued ASU No.&amp;#xA0;2014-09, &amp;#x201C;Revenue
 from Contracts with Customers&amp;#x201D; (&amp;#x201C;ASU 2014-09&amp;#x201D;),
 which requires entities to recognize revenue in a way that depicts
 the transfer of promised goods or services to customers in an
 amount that reflects the consideration to which the entity expects
 to be entitled to in exchange for those goods or services. The new
 guidance also requires additional disclosure about the nature,
 amount, timing and uncertainty of revenue and cash flows arising
 from customer contracts, including significant judgments and
 changes in judgments and assets recognized from costs incurred to
 obtain or fulfill a contract. In July 2015, the FASB voted to delay
 the effective date of ASU 2014-09 by one year to the first quarter
 of 2018 to provide companies sufficient time to implement the
 standards. Early adoption will be permitted, but not before the
 first quarter of 2017. Adoption can occur using one of two
 prescribed transition methods. In March and April 2016, the FASB
 issued ASU 2016-08, &amp;#x201C;Revenue from Contracts with Customers:
 Principal versus Agent Considerations (Reporting Revenue Gross
 versus Net)&amp;#x201D; and ASU 2016-10, &amp;#x201C;Revenue from Contracts
 with Customers: Identifying Performance Obligations and
 Licensing&amp;#x201D; which provide supplemental adoption guidance and
 clarification to ASC 2014-09. ASU 2016-08 and ASU 2016-10 must be
 adopted concurrently with the adoption of ASU 2014-09. The Company
 is currently evaluating the impact of these new standards.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In August 2014, the FASB issued ASU No.&amp;#xA0;2014-15,
 &amp;#x201C;Disclosure of Uncertainties About an Entity&amp;#x2019;s Ability
 to Continue as a Going Concern&amp;#x201D; (&amp;#x201C;ASU 2014-15&amp;#x201D;),
 which provides guidance on management&amp;#x2019;s responsibility in
 evaluating whether there is substantial doubt about an
 entity&amp;#x2019;s ability to continue as a going concern and to
 provide related footnote disclosures. ASU 2014-15 is effective for
 the annual period ending after December&amp;#xA0;15, 2016, and for
 annual and interim periods thereafter. The adoption of ASU 2014-15
 is not expected to have a material impact on our financial
 position, results of operations or cash flows.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 During January 2016, the FASB issued ASU No.&amp;#xA0;2016-01,
 &amp;#x201C;Financial Instruments &amp;#x2014; Overall: Recognition and
 Measurement of Financial Assets and Financial Liabilities
 (&amp;#x201C;ASU 2016-01&amp;#x201D;). The standard addresses certain aspects
 of recognition, measurement, presentation, and disclosure of
 financial instruments. This ASU is effective for fiscal years, and
 interim periods within those years, beginning after
 December&amp;#xA0;15, 2017. Early adoption is not permitted with the
 exception of certain provisions related to the presentation of
 other comprehensive income. The adoption of ASU 2016-01 is not
 expected to have a material impact on our financial position,
 results of operations or cash flows.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 During February 2016, the FASB issued ASU No.&amp;#xA0;2016-02,
 &amp;#x201C;Leases&amp;#x201D; (&amp;#x201C;ASU 2016-02&amp;#x201D;). The standard
 requires lessees to recognize a lease liability and a lease asset
 for all leases, including operating leases, with a term greater
 than 12 months on its balance sheet. The update also expands the
 required quantitative and qualitative disclosures surrounding
 leases. ASU 2016-02 is effective for fiscal years beginning after
 December&amp;#xA0;15, 2018, including interim periods within those
 fiscal years. The Company is currently evaluating the impact of the
 new standard.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In March 2016, the FASB issued ASU No.&amp;#xA0;2016-06,
 &amp;#x201C;Contingent Put and Call Option in Debt Instruments&amp;#x201D;
 (&amp;#x201C;ASU 2016-06&amp;#x201D;). ASU 2016-06 is intended to simplify
 the analysis of embedded derivatives for debt instruments that
 contain contingent put or call options. The amendments in ASU
 2016-06 clarify that an entity is required to assess the embedded
 call or put options solely in accordance with the four-step
 decision sequence. Consequently, when a call (put) option is
 contingently exercisable, an entity does not have to initially
 assess whether the event that triggers the ability to exercise a
 call (put) option is related to interest rates or credit risks. The
 amendments in ASU 2016-06 take effect for public business entities
 for financial statements issued for fiscal years beginning after
 December&amp;#xA0;15, 2016, and interim periods within those fiscal
 years. Early adoption is permitted, including adoption in an
 interim period. The Company does not expect the adoption of ASU
 2016&amp;#x2013;01 to have a significant impact on its financial
 statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In March 2016, FASB issued ASU No.&amp;#xA0;2016-09,
 &amp;#x201C;Improvements to Employee Share-based Payment
 Accounting&amp;#x201D; (&amp;#x201C;ASU 2016-09&amp;#x201D;). ASU 2016-09
 simplifies several aspects of the accounting for employee
 share-based payment transactions for both public and nonpublic
 entities, including the accounting for income taxes, forfeitures,
 and statutory tax withholding requirements, as well as
 classification in the statement of cash flows. ASU 2016-09 is
 effective for annual periods beginning after December&amp;#xA0;15,
 2016, and interim periods within those annual periods. The Company
 is currently evaluating the standard and the impact on its
 financial statements and footnote disclosures.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In August 2016, FASB issued ASU No.&amp;#xA0;2016-15,
 &amp;#x201C;Classification of Certain Cash Receipts and Cash
 Payments&amp;#x201D; (&amp;#x201C;ASU 2016-15&amp;#x201D;). ASU 2016-15 clarifies
 the presentation and classification of certain cash receipts and
 cash payments in the statement of cash flows. ASU 2016-15 is
 effective for fiscal years, and interim periods within those years
 beginning after December&amp;#xA0;15, 2017. Early adoption is
 permitted. The Company does not expect the adoption of ASU
 No.&amp;#xA0;2016-15 to have a material impact on its financial
 statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 Management does not believe there would have been a material effect
 on the accompanying financial statements had any other recently
 issued, but not yet effective, accounting standards been adopted in
 the current period.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:AccountingChangesAndErrorCorrectionsTextBlock>
  <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_3_15">205000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
  <us-gaap:EarningsPerShareTextBlock contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" id="id_11091862_69879649-51A6-45D4-9415-727426F47812_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;11. Net Loss Per Share&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 For the three and nine month periods ended September&amp;#xA0;30, 2016
 and 2015, certain potential shares of common stock have been
 excluded from the calculation of loss per share because the
 exercise price was greater than the average market price of our
 common stock, and therefore, the effect would have been
 anti-dilutive. In addition, incremental shares from the assumed
 conversion of the MHR note payable are excluded, as the effect of
 these shares is anti-dilutive. The following table sets forth the
 number of potential shares of common stock that have been excluded
 from diluted net income per share because their effect was
 anti-dilutive.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;September&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Nine Months Ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;September&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Options to purchase common shares&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,219,100&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,390,750&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,219,100&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,390,750&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,997,775&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;25,008,082&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,997,775&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;25,008,082&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 MHR convertible notes payable&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;45,824,469&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;40,297,635&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;45,824,469&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;40,297,635&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;77,051,651&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,896,702&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;77,051,651&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;74,132,112&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" id="id_11091862_15EBE9C9-8CD6-404A-96F6-0E36F0106F18_1_2">P1Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" id="id_11091862_6A1EEFF4-B638-416A-9B90-6C938076CED2_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;8. Accounts Payable and Accrued Expenses&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Accounts payable and accrued expenses consist of the following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="68%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&amp;#xA0;2016&lt;br /&gt;
 (unaudited)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(In
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accounts payable&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;431&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,762&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accrued legal, professional and other fees&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;285&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;304&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accrued vacation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;57&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;55&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;773&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,121&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
  <us-gaap:Revenues contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_3_0">863000</us-gaap:Revenues>
  <us-gaap:InterestExpenseRelatedParty contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_3_16">8110000</us-gaap:InterestExpenseRelatedParty>
  <us-gaap:InventoryDisclosureTextBlock contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" id="id_11091862_746AC4EF-1FB5-44B3-9C84-034F56CCC0BC_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;5. Inventory&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Inventory consists of the following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2016&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(unaudited)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;(In&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Raw Materials&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;558&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Finished Goods&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;85&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;782&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;85&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,340&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_3_17">-7873000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_3_12">12000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" id="id_11091862_9A80020F-0FC9-4192-B8E5-994C1BA76474_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 In accordance with FASB ASC 820, &lt;i&gt;&amp;#x201C;Fair Value Measurements
 and Disclosures,&amp;#x201D;&lt;/i&gt; the following table represents the
 Company&amp;#x2019;s fair value hierarchy for its financial assets and
 liabilities measured at fair value on a recurring basis as of
 September&amp;#xA0;30, 2016 and December&amp;#xA0;31, 2015:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="61%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;September&amp;#xA0;30, 2016&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; WIDTH: 66.85pt; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;(unaudited)&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(In&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(In&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(In&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Derivative Instruments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,269&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;39,730&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;49,999&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="16"&gt;&lt;/td&gt;
 &lt;td height="16" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="16" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="16" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; WIDTH: 64.65pt; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;December&amp;#xA0;31, 2015&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;(In
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(In&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(In&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Derivative Instruments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,343&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;35,623&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;47,966&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" id="id_11091862_146A2FFC-B6F6-4F98-BCDE-95533926A1CB_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;7. Equipment and Leasehold Improvements, Net&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="55%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Useful&amp;#xA0;Lives&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;in Years&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;September&amp;#xA0;30,&amp;#xA0;2016&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(unaudited)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(in&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;b&gt;3-7&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;601&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;601&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Leasehold improvements&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 &lt;b&gt;Term&amp;#xA0;of&amp;#xA0;lease&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;628&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;628&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Less: accumulated depreciation and amortization&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;627&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;616&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Equipment and leasehold improvements, net&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <us-gaap:GrossProfit contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_3_3">-490000</us-gaap:GrossProfit>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" id="id_11091862_930404A4-E15F-465A-8A6B-716B21689ED6_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;13. Income Taxes&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The Company is primarily subject to United States federal and New
 Jersey state income tax. The Company&amp;#x2019;s policy is to recognize
 interest and penalties related to income tax matters in income tax
 expense. As of December&amp;#xA0;31, 2015 and September&amp;#xA0;30, 2016,
 the Company had no accruals for interest or penalties related to
 income tax matters.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:OperatingExpenses contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_3_9">6182000</us-gaap:OperatingExpenses>
  <us-gaap:NetIncomeLoss contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_3_18">-14545000</us-gaap:NetIncomeLoss>
  <us-gaap:IncreaseDecreaseInDeferredLiabilities contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_0D79EF6F-344B-4AD3-ADFC-27ADB3DF6AC0_1_15">-7000</us-gaap:IncreaseDecreaseInDeferredLiabilities>
  <us-gaap:InventoryWriteDown contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_3_2">1214000</us-gaap:InventoryWriteDown>
  <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" id="id_11091862_E159AC25-6F5A-4BBE-A97E-E0A47C0EC533_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="55%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Useful&amp;#xA0;Lives&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;in Years&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;September&amp;#xA0;30,&amp;#xA0;2016&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(unaudited)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(in&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;b&gt;3-7&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;601&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;601&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Leasehold improvements&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 &lt;b&gt;Term&amp;#xA0;of&amp;#xA0;lease&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;628&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;628&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Less: accumulated depreciation and amortization&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;627&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;616&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Equipment and leasehold improvements, net&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_0D79EF6F-344B-4AD3-ADFC-27ADB3DF6AC0_1_9">-223000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_0D79EF6F-344B-4AD3-ADFC-27ADB3DF6AC0_1_11">-887000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" id="id_11091862_B0199169-66F6-4092-A45B-7BB736875BF6_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 In July 2015, the FASB issued ASU
 No.&amp;#xA0;2015-11,&amp;#xA0;&amp;#x201C;Simplifying the Measurement of
 Inventory&amp;#x201D; (&amp;#x201C;ASU 2015-11&amp;#x201D;). ASU 2015-11 requires
 that inventory within the scope of the guidance be measured at the
 lower of cost and net realizable value. Inventory measured using
 last-in, first-out and retail inventory method are excluded from
 this new guidance. This ASU replaces the concept of market with the
 single measurement of net realizable value and is intended to
 create efficiencies for preparers and more closely aligns U.S. GAAP
 with IFRS. This ASU is effective for public business entities in
 fiscal years beginning after December&amp;#xA0;15, 2016, including
 interim periods within those years. Prospective application is
 required and early adoption is permitted as of the beginning of an
 interim or annual reporting period. The Company is currently
 evaluating the impact of the new standards.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 In April&amp;#xA0;2015, the FASB issued ASU 2015-03, &amp;#x201C;Interest
 &amp;#x2013; Imputation of Interest&amp;#x201D; (&amp;#x201C;ASU 2015-03&amp;#x201D;),
 which requires that debt issuance costs related to a recognized
 debt liability be presented in the balance sheet as a direct
 deduction from the carrying amount of that debt liability,
 consistent with debt discounts. The recognition and measurement
 guidance for debt issuance costs are not affected by the amendments
 in this ASU. ASU 2015-03 is effective for annual and interim
 periods beginning on or after December&amp;#xA0;15, 2015. The adoption
 of ASU 2015-03 did not have a material impact on our financial
 position, results of operations or cash flows.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In May 2014, the FASB issued ASU No.&amp;#xA0;2014-09, &amp;#x201C;Revenue
 from Contracts with Customers&amp;#x201D; (&amp;#x201C;ASU 2014-09&amp;#x201D;),
 which requires entities to recognize revenue in a way that depicts
 the transfer of promised goods or services to customers in an
 amount that reflects the consideration to which the entity expects
 to be entitled to in exchange for those goods or services. The new
 guidance also requires additional disclosure about the nature,
 amount, timing and uncertainty of revenue and cash flows arising
 from customer contracts, including significant judgments and
 changes in judgments and assets recognized from costs incurred to
 obtain or fulfill a contract. In July 2015, the FASB voted to delay
 the effective date of ASU 2014-09 by one year to the first quarter
 of 2018 to provide companies sufficient time to implement the
 standards. Early adoption will be permitted, but not before the
 first quarter of 2017. Adoption can occur using one of two
 prescribed transition methods. In March and April 2016, the FASB
 issued ASU 2016-08, &amp;#x201C;Revenue from Contracts with Customers:
 Principal versus Agent Considerations (Reporting Revenue Gross
 versus Net)&amp;#x201D; and ASU 2016-10, &amp;#x201C;Revenue from Contracts
 with Customers: Identifying Performance Obligations and
 Licensing&amp;#x201D; which provide supplemental adoption guidance and
 clarification to ASC 2014-09. ASU 2016-08 and ASU 2016-10 must be
 adopted concurrently with the adoption of ASU 2014-09. The Company
 is currently evaluating the impact of these new standards.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In August 2014, the FASB issued ASU No.&amp;#xA0;2014-15,
 &amp;#x201C;Disclosure of Uncertainties About an Entity&amp;#x2019;s Ability
 to Continue as a Going Concern&amp;#x201D; (&amp;#x201C;ASU 2014-15&amp;#x201D;),
 which provides guidance on management&amp;#x2019;s responsibility in
 evaluating whether there is substantial doubt about an
 entity&amp;#x2019;s ability to continue as a going concern and to
 provide related footnote disclosures. ASU 2014-15 is effective for
 the annual period ending after December&amp;#xA0;15, 2016, and for
 annual and interim periods thereafter. The adoption of ASU 2014-15
 is not expected to have a material impact on our financial
 position, results of operations or cash flows.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 During January 2016, the FASB issued ASU No.&amp;#xA0;2016-01,
 &amp;#x201C;Financial Instruments &amp;#x2014; Overall: Recognition and
 Measurement of Financial Assets and Financial Liabilities
 (&amp;#x201C;ASU 2016-01&amp;#x201D;). The standard addresses certain aspects
 of recognition, measurement, presentation, and disclosure of
 financial instruments. This ASU is effective for fiscal years, and
 interim periods within those years, beginning after
 December&amp;#xA0;15, 2017. Early adoption is not permitted with the
 exception of certain provisions related to the presentation of
 other comprehensive income. The adoption of ASU 2016-01 is not
 expected to have a material impact on our financial position,
 results of operations or cash flows.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 During February 2016, the FASB issued ASU No.&amp;#xA0;2016-02,
 &amp;#x201C;Leases&amp;#x201D; (&amp;#x201C;ASU 2016-02&amp;#x201D;). The standard
 requires lessees to recognize a lease liability and a lease asset
 for all leases, including operating leases, with a term greater
 than 12 months on its balance sheet. The update also expands the
 required quantitative and qualitative disclosures surrounding
 leases. ASU 2016-02 is effective for fiscal years beginning after
 December&amp;#xA0;15, 2018, including interim periods within those
 fiscal years. The Company is currently evaluating the impact of the
 new standard.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In March 2016, the FASB issued ASU No.&amp;#xA0;2016-06,
 &amp;#x201C;Contingent Put and Call Option in Debt Instruments&amp;#x201D;
 (&amp;#x201C;ASU 2016-06&amp;#x201D;). ASU 2016-06 is intended to simplify
 the analysis of embedded derivatives for debt instruments that
 contain contingent put or call options. The amendments in ASU
 2016-06 clarify that an entity is required to assess the embedded
 call or put options solely in accordance with the four-step
 decision sequence. Consequently, when a call (put) option is
 contingently exercisable, an entity does not have to initially
 assess whether the event that triggers the ability to exercise a
 call (put) option is related to interest rates or credit risks. The
 amendments in ASU 2016-06 take effect for public business entities
 for financial statements issued for fiscal years beginning after
 December&amp;#xA0;15, 2016, and interim periods within those fiscal
 years. Early adoption is permitted, including adoption in an
 interim period. The Company does not expect the adoption of ASU
 2016&amp;#x2013;01 to have a significant impact on its financial
 statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In March 2016, FASB issued ASU No.&amp;#xA0;2016-09,
 &amp;#x201C;Improvements to Employee Share-based Payment
 Accounting&amp;#x201D; (&amp;#x201C;ASU 2016-09&amp;#x201D;). ASU 2016-09
 simplifies several aspects of the accounting for employee
 share-based payment transactions for both public and nonpublic
 entities, including the accounting for income taxes, forfeitures,
 and statutory tax withholding requirements, as well as
 classification in the statement of cash flows. ASU 2016-09 is
 effective for annual periods beginning after December&amp;#xA0;15,
 2016, and interim periods within those annual periods. The Company
 is currently evaluating the standard and the impact on its
 financial statements and footnote disclosures.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In August 2016, FASB issued ASU No.&amp;#xA0;2016-15,
 &amp;#x201C;Classification of Certain Cash Receipts and Cash
 Payments&amp;#x201D; (&amp;#x201C;ASU 2016-15&amp;#x201D;). ASU 2016-15 clarifies
 the presentation and classification of certain cash receipts and
 cash payments in the statement of cash flows. ASU 2016-15 is
 effective for fiscal years, and interim periods within those years
 beginning after December&amp;#xA0;15, 2017. Early adoption is
 permitted. The Company does not expect the adoption of ASU
 No.&amp;#xA0;2016-15 to have a material impact on its financial
 statements.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:IncreaseDecreaseInInventories contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_0D79EF6F-344B-4AD3-ADFC-27ADB3DF6AC0_1_10">-41000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_3_10">-6672000</us-gaap:OperatingIncomeLoss>
  <us-gaap:LineOfCreditFacilityDescription contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" id="id_11091862_E6B10C6E-8C3F-4B97-873A-139EC4AC863A_1_0">Loan will mature on the earlier of (a) December 31, 2019 and, (b) 30 days  after the end of any fiscal year in which the Company&apos;s cash (plus certain cash  expenditures during such fiscal year that are unrelated to the B12 Product or  related products) as of the end of such fiscal year (subject to certain  permitted deductions) is more than three times the principal amount of the Loan  as of the end of such fiscal year.</us-gaap:LineOfCreditFacilityDescription>
  <us-gaap:IncreaseDecreaseInRoyaltiesPayable contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_0D79EF6F-344B-4AD3-ADFC-27ADB3DF6AC0_1_13">173000</us-gaap:IncreaseDecreaseInRoyaltiesPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_0D79EF6F-344B-4AD3-ADFC-27ADB3DF6AC0_1_14">-1348000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_0D79EF6F-344B-4AD3-ADFC-27ADB3DF6AC0_1_12">-2000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" id="id_11091862_09A01584-B8DB-4DE3-BD0B-1871D978DE6A_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;2. Basis of Presentation&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The condensed balance sheet at December&amp;#xA0;31, 2015 was derived
 from audited financial statements but does not include all
 disclosures required by accounting principles generally accepted in
 the United States of America. The other information in these
 condensed financial statements is unaudited but, in the opinion of
 management, reflects all adjustments necessary for a fair
 presentation of the results for the periods covered. All such
 adjustments are of a normal recurring nature unless disclosed
 otherwise. These condensed financial statements, including notes,
 have been prepared in accordance with the applicable rules of the
 Securities and Exchange Commission (the &amp;#x201C;SEC&amp;#x201D;) and do
 not include all of the information and disclosures required by
 accounting principles generally accepted in the United States of
 America for complete financial statements. These condensed
 financial statements should be read in conjunction with the
 financial statements and additional information as contained in our
 Annual Report on Form 10-K for the year ended December&amp;#xA0;31,
 2015. Results of operations for the nine-month period ended
 September&amp;#xA0;30, 2016 are not necessarily indicative of the
 operating results that may be expected for the year ending
 December&amp;#xA0;31, 2016.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Certain prior period amounts have been reclassified to conform to
 current period presentation.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_0D79EF6F-344B-4AD3-ADFC-27ADB3DF6AC0_1_17">-5384000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" unitRef="shares" decimals="INF" id="id_11091862_15EBE9C9-8CD6-404A-96F6-0E36F0106F18_1_3">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:RoyaltyExpense contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_512FF41A-3593-42B5-AA28-786968DFF670_2_0">173000</us-gaap:RoyaltyExpense>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_0D79EF6F-344B-4AD3-ADFC-27ADB3DF6AC0_1_4">225000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" id="id_11091862_4F3EBE90-393A-4541-8B97-25A655C48657_1_0">&lt;div&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The following weighted-average assumptions were used for grants
 made under the stock option plans for the nine months ended
 September&amp;#xA0;30, 2016:&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="68%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="89%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;145.82&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Expected term (years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.79&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Risk free rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.82&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Annual forfeiture rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14.523&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" id="id_11091862_3B51AAB6-FCE7-421B-9B7F-194C2EA042A1_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The following table sets forth the number of potential shares of
 common stock that have been excluded from diluted net income per
 share because their effect was anti-dilutive.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;September&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Nine Months Ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;September&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Options to purchase common shares&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,219,100&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,390,750&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,219,100&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,390,750&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,997,775&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;25,008,082&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,997,775&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;25,008,082&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 MHR convertible notes payable&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;45,824,469&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;40,297,635&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;45,824,469&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;40,297,635&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;77,051,651&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,896,702&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;77,051,651&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;74,132,112&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" id="id_11091862_8076083C-C152-4DB0-B2D3-811781600D1B_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Inventory consists of the following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2016&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(unaudited)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;(In&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Raw Materials&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;558&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Finished Goods&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;85&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;782&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;85&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,340&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" unitRef="pure" decimals="2" id="id_11091862_64B2D8D8-53A7-4C5C-9FA5-BF51CB9D1299_1_3">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ScheduleOfDerivativeInstrumentsTextBlock contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" id="id_11091862_B612A9FA-253A-4196-96B4-8E0FA500B97D_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Derivative instruments consist of the following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&amp;#xA0;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(unaudited)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Convertible Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;34,388&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;30,823&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Reimbursement Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,277&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,118&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Bridge Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,628&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,130&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Amended and Restated August 2009 Warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,812&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,142&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Amended and Restated June 2010 MHR Warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;437&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;552&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Amended and Restated August 2010 Warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,275&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,507&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Amended and Restated August 2010 MHR Waiver Warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;474&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;560&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Amended and Restated July 2011 Warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,463&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,729&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 July 2011 Investor Warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;205&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Amended and Restated July 2011 MHR Waiver Warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;386&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;456&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 May 2013 MHR Modification Warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,859&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,744&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;49,999&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;47,966&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsTextBlock>
  <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" id="id_11091862_08BEFFAA-8A36-4679-A27F-21DBA9994D0D_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 As of September&amp;#xA0;30, 2016, future minimum rental payments are
 as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="84%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="13%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; WIDTH: 95.55pt; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;Years Ending December&amp;#xA0;31,&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;(In&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2016 (remaining)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;24&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;74&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;129&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
  <dei:TradingSymbol contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" id="id_11091862_6E78A933-93B9-40DD-99D6-BFF25EB74C68_1_0">EMIS</dei:TradingSymbol>
  <us-gaap:RestructuringAndRelatedActivitiesInitiationDate contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" id="id_11091862_68BBF9A2-2E68-469B-BBFD-90E22729A22D_1_0">2014-08-20</us-gaap:RestructuringAndRelatedActivitiesInitiationDate>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_3_5">260000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" id="id_11091862_45265350-80EC-4A9B-B6FF-99201C2DE166_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 The carrying value of the MHR Notes is comprised of the
 following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="68%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;September&amp;#xA0;30,&amp;#xA0;2016&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(unaudited)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Convertible Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;49,650&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;46,542&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Loan Agreement&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;24,342&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;22,801&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Bridge Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,258&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,115&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Reimbursement Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;794&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;755&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Unamortized discounts&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(12,735&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(11,041&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;64,309&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;61,172&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" unitRef="pure" decimals="4" id="id_11091862_64B2D8D8-53A7-4C5C-9FA5-BF51CB9D1299_1_0">1.4582</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" id="id_11091862_64363B3D-5815-4FC0-AA5F-02328FDB0D98_1_0">&lt;div&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Oral Eligen B12&amp;#x2122; Rx Product&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 We sell our oral Eligen B12&amp;#x2122; Rx product through drug
 wholesalers and retail pharmacies. We recognize revenue from
 prescription product sales, net of sales discounts, chargebacks,
 and rebates. We accept returns of unsalable product from customers
 within a return period of six months prior to and 12 months
 following product expiration. Our oral Eligen B12&amp;#x2122; Rx product
 currently has a shelf life of 24 months from the date of
 manufacture. Given the limited history of our oral Eligen
 B12&amp;#x2122; Rx product, we currently cannot reliably estimate
 expected returns of the prescription products at the time of
 shipment. Accordingly, we will defer recognition of revenue on
 prescription products until the right of return no longer exists,
 which occurs at the earlier of the time the oral Eligen B12&amp;#x2122;
 Rx product is dispensed through patient prescriptions or expiration
 of the right of return.&lt;/p&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Collaborative Agreements and Feasibility Studies&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Revenue earned from collaborative agreements and feasibility
 studies is comprised of reimbursed research and development costs,
 as well as upfront and research and development milestone payments.
 Deferred revenue represents payments received which are related to
 future performance. Revenue from feasibility studies, which are
 typically short term in nature, is recognized upon delivery of the
 study, provided that all other revenue recognition criteria are
 met.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Revenue from collaboration agreements are recognized using the
 proportional performance method provided that we can reasonably
 estimate the level of effort required to complete our performance
 obligations under an arrangement and such performance obligations
 are provided on a best effort basis and based on &amp;#x201C;expected
 payments.&amp;#x201D; Under the proportional performance method,
 periodic revenue related to nonrefundable cash payments is
 recognized as the percentage of actual effort expended to date as
 of that period to the total effort expected for all of our
 performance obligations under the arrangement. Actual effort is
 generally determined based upon actual hours incurred and include
 research and development (&amp;#x201C;R&amp;amp;D&amp;#x201D;) activities
 performed by us and time spent for Joint Steering Committee
 (&amp;#x201C;JSC&amp;#x201D;) activities. Total expected effort is generally
 based upon the total R&amp;amp;D and JSC hours incorporated into the
 project plan that is agreed to by both parties to the
 collaboration. Significant management judgments and estimates are
 required in determining the level of effort required under an
 arrangement and the period over which we expect to complete the
 related performance obligations. Estimates of the total expected
 effort included in each project plan are based on historical
 experience of similar efforts and expectations based on the
 knowledge of scientists for both the Company and its collaboration
 partners. The Company periodically reviews and updates the project
 plan for each collaborative agreement. The most recent reviews took
 place in January 2016. In the event that a change in estimate
 occurs, the change will be accounted for using the cumulative
 catch-up method which provides for an adjustment to revenue in the
 current period. Estimates of our level of effort may change in the
 future, resulting in a material change in the amount of revenue
 recognized in future periods.&lt;/p&gt;
 &lt;p style="font-size:1px;margin-top:12px;margin-bottom:0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Generally, under collaboration arrangements, nonrefundable payments
 received during the period of performance may include time- or
 performance-based milestones. The proportion of actual performance
 to total expected performance is applied to the &amp;#x201C;expected
 payments&amp;#x201D; in determining periodic revenue. However, revenue
 is limited to the sum of (i)&amp;#xA0;the amount of nonrefundable cash
 payments received and (ii)&amp;#xA0;the payments that are contractually
 due but have not yet been paid.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 With regard to revenue recognition in connection with development
 and license agreements that include multiple deliverables,
 Emisphere&amp;#x2019;s management reviews the relevant terms of the
 agreements and determines whether such deliverables should be
 accounted for as a single unit of accounting in accordance with
 FASB ASC 605-25, &lt;i&gt;Multiple-Element Arrangements&lt;/i&gt;. If it is
 determined that a delivered license and Eligen &lt;sup style="font-size:85%; vertical-align:top"&gt;&amp;#xAE;&lt;/sup&gt; Technology do not
 have stand-alone value and Emisphere does not have objective
 evidence of fair value of the undelivered Eligen &lt;sup style="font-size:85%; vertical-align:top"&gt;&amp;#xAE;&lt;/sup&gt; Technology or the
 manufacturing value of all the undelivered items, then such
 deliverables are accounted for as a single unit of accounting and
 any payments received pursuant to such agreement, including any
 upfront or development milestone payments and any payments received
 for support services, will be deferred and included in deferred
 revenue within our balance sheet until such time as management can
 estimate when all of such deliverables will be delivered, if ever.
 Management reviews and reevaluates such conclusions as each item in
 the arrangement is delivered and circumstances of the development
 arrangement change.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:SellingAndMarketingExpense contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_3_7">1868000</us-gaap:SellingAndMarketingExpense>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" unitRef="pure" decimals="4" id="id_11091862_64B2D8D8-53A7-4C5C-9FA5-BF51CB9D1299_1_2">0.0182</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_0D79EF6F-344B-4AD3-ADFC-27ADB3DF6AC0_1_7">254000</us-gaap:ShareBasedCompensation>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" id="id_11091862_64B2D8D8-53A7-4C5C-9FA5-BF51CB9D1299_1_1">P6Y9M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" id="id_11091862_BA5A756D-27AC-4535-9BA4-8CDFFCD5FBF2_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Accounts payable and accrued expenses consist of the following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="68%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&amp;#xA0;2016&lt;br /&gt;
 (unaudited)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(In
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accounts payable&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;431&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,762&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accrued legal, professional and other fees&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;285&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;304&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accrued vacation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;57&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;55&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;773&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,121&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfDebtTableTextBlock contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" id="id_11091862_577F9133-23A6-49C0-A3A5-BBD12B3F295E_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Notes payable, related party, net of related discounts, consists of
 the following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="68%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;September&amp;#xA0;30,&amp;#xA0;2016&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(unaudited)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Convertible Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;39,067&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;37,450&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Loan Agreement&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;24,342&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;22,801&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Bridge Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;106&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;166&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Reimbursement Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;794&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;755&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;64,309&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;61,172&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Less: Current portion&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Non-current notes payable, net of related discounts&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;57,309&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;54,172&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" unitRef="shares" decimals="0" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_3_20">60687478</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <emis:AdjustedFreeCashFlowIncome contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" unitRef="iso4217_USD" decimals="-6" id="id_11091862_A66E1C27-E70A-4974-A071-E703602E5FC8_1_2">50000000</emis:AdjustedFreeCashFlowIncome>
  <emis:CashSweepAsPercentageOfConsolidatedFreeCashFlow contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" unitRef="pure" decimals="2" id="id_11091862_02836261-D58A-47B4-ADB3-D1CE86585ED8_1_3">0.75</emis:CashSweepAsPercentageOfConsolidatedFreeCashFlow>
  <emis:PrepaidExpensesAndOtherCurrentAssetsTextBlock contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" id="id_11091862_EEB1FCFA-57D2-4BD3-A82D-E390AE4F22E0_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;6. Prepaid Expenses and Other Current Assets&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Prepaid expenses and other current assets consist of the
 following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="68%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;September&amp;#xA0;30,&amp;#xA0;2016&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(unaudited)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Prepaid corporate insurance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;40&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;93&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Deposit on inventory&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;184&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Prepaid expenses and other current assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;154&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;804&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;194&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,081&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</emis:PrepaidExpensesAndOtherCurrentAssetsTextBlock>
  <emis:OperatingLeaseExpirationPeriod contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" id="id_11091862_09357B0E-68AB-4E68-8A5C-74A6B3AB7394_1_0">2017</emis:OperatingLeaseExpirationPeriod>
  <emis:CashSweepAsPercentageOfConsolidatedFreeCashFlowUponConditions contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" unitRef="pure" decimals="2" id="id_11091862_A66E1C27-E70A-4974-A071-E703602E5FC8_1_1">0.75</emis:CashSweepAsPercentageOfConsolidatedFreeCashFlowUponConditions>
  <emis:ShelfLifeOfProducts contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" id="id_11091862_671556E7-8220-46AC-9CAF-CBF8D01DD5B4_3_1">P24M</emis:ShelfLifeOfProducts>
  <emis:MinimumPercentageOfCommonStockOutstandingToProvideContinuityToNomineeOnBoard contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" unitRef="pure" decimals="INF" id="id_11091862_68BBF9A2-2E68-469B-BBFD-90E22729A22D_1_1">0.02</emis:MinimumPercentageOfCommonStockOutstandingToProvideContinuityToNomineeOnBoard>
  <emis:NatureOfOperationsAndLiquidityTextBlock contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" id="id_11091862_05B3B3F9-B6C5-4BEC-BD0F-EFFCC95B09D8_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;1. Nature of Operations and Liquidity&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;Nature of Operations.&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Emisphere Technologies, Inc. (&amp;#x201C;Emisphere,&amp;#x201D; &amp;#x201C;the
 Company,&amp;#x201D; &amp;#x201C;our,&amp;#x201D; &amp;#x201C;us,&amp;#x201D; or
 &amp;#x201C;we&amp;#x201D;) is a commercial stage pharmaceutical and drug
 delivery company. We are in partnership with global pharmaceutical
 companies to develop new formulations of existing products, as well
 as new chemical entities, using our Eligen&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;&amp;#xA0;Technology. We launched our
 first prescription medical food product, oral Eligen B12 in the
 U.S. in March 2015, and we are currently engaged in strategic
 discussions to optimize its economic value in the U.S. and global
 markets. Beyond Eligen B12, we utilize our proprietary
 Eligen&amp;#xA0;&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;&amp;#xA0;Technology to create new oral
 formulations of therapeutic agents. Our product pipeline includes
 prescription drug and medical food product candidates that are
 being developed in partnership or internally.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Our core business strategy is to build new, high-value partnerships
 and expand upon our existing partnerships, to enter into strategic
 transactions or alliances to realize the full economic potential of
 the oral Eligen B12 product, evaluate commercial opportunities for
 new prescription medical foods, and promote new uses for our
 Eligen&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;&amp;#xA0;Technology, a broad based
 proprietary oral drug delivery platform which makes it possible to
 avoid injections for drug administration through the use of
 delivery agents, or carriers, which facilitate or enable transport
 of therapeutic molecules, including large peptides and proteins,
 across biological membranes such as those of the gastrointestinal
 tract.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;Liquidity and Capital Resources&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Since our inception in 1986, we have generated significant losses
 from operations and we anticipate that we will continue to generate
 significant losses from operations for the foreseeable future, and
 that in order to continue as a going concern, our business will
 require substantial additional investment that we have not yet
 secured.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 As of September&amp;#xA0;30, 2016, our accumulated deficit was
 approximately $569.1 million; our stockholder&amp;#x2019;s deficit was
 $166.2 million. Net loss was $5.2 million compared to a net loss of
 $4.4 million for the three months ended September&amp;#xA0;30, 2016 and
 2015, respectively; our net loss was $14.5 million and $30.3
 million for the nine months ended September&amp;#xA0;30, 2016 and 2015,
 respectively. On September&amp;#xA0;30, 2016 we had approximately $7.5
 million in cash. We have limited capital resources and operations
 to date have been funded with the proceeds from collaborative
 research agreements, private and public debt and equity financings
 and income earned on investments.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 As of September&amp;#xA0;30, 2016, our financial obligations included
 approximately $49.7 million (face value) under our Second Amended
 and Restated Convertible Notes (the &amp;#x201C;Convertible
 Notes&amp;#x201D;), approximately $24.3 million (face value) under a
 loan agreement entered into on August&amp;#xA0;20, 2014 (the
 &amp;#x201C;Loan Agreement&amp;#x201D;), approximately $0.8 million (face
 value) under our Second Amended and Restated Reimbursement Notes
 (the &amp;#x201C;Reimbursement Notes&amp;#x201D;), and approximately $2.3
 million (face value) under our Second Amended and Restated Bridge
 Notes (the &amp;#x201C;Bridge Notes&amp;#x201D;). The Convertible Notes and
 the Loan Agreement are subject to annual net sales performance
 targets.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Under the terms of the Loan Agreement, described in Note 9 to the
 Financial Statements, we borrowed an aggregate of $20.0 million to
 finance the development, manufacturing, marketing and sales of our
 oral Eligen B12 Rx Product. The loan facility will mature on
 December&amp;#xA0;31, 2019 and bears interest at a rate of 13%&amp;#xA0;per
 year. In the event that we do not satisfy annual net sales targets
 of Eligen B12 by December&amp;#xA0;31 for each fiscal year beginning
 2015 through 2019, we will be in default under the Loan Agreement.
 We do not anticipate meeting the annual sales target at
 December&amp;#xA0;31, 2016, however, the Company is currently in
 discussions with the creditor for a permanent waiver of this
 condition.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 On October&amp;#xA0;26, 2015, we received a total payment of $14
 million from Novo Nordisk pursuant to, and consisting of, $5
 million as payment for entry into the Expansion License Agreement
 and $9 million as prepayment of a product development milestone and
 in exchange for a reduction in certain future royalty payments that
 may have become due and payable under the terms of our GLP-1
 Development License Agreement with Novo Nordisk.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Under the terms of our loan agreements, we are obligated to pre-pay
 certain loans and notes using 50% of any extraordinary receipts,
 such as the $14 million received from Novo Nordisk. The creditor
 under our Loan Agreement and Reimbursement Notes has agreed to
 extend the date by which we are required to use 50% of the $14
 million received from Novo Nordisk to pre-pay certain loans and
 notes until November&amp;#xA0;15, 2016. Because the Loan Prepayment
 deadline has not been extended beyond one year from
 September&amp;#xA0;30, 2016, we have classified $7.0 million of the
 loans and notes as a current liability as of September&amp;#xA0;30,
 2016.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 We believe that our current cash balance will provide sufficient
 capital to continue operations through November 2016. However, if
 the pre-payment obligation is further extended or waived, the
 Company will have sufficient cash to operate through approximately
 December 2017. The Company&amp;#x2019;s future capital requirements
 beyond November 2016 (or December 2017, in the event the
 pre-payment obligation is further extended or waived) and our
 financial success depend largely on our ability to raise additional
 capital, including by leveraging existing and securing new
 partnering opportunities for Eligen B12 and the Eligen&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;&amp;#xA0;Technology.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 While our plan is to raise capital from product partnering
 opportunities and/or commercial operations to address our capital
 deficiencies and meet our operating cash requirements, there is no
 assurance that our plans will be successful. If we fail to generate
 sufficient capital from commercial operations or partnerships, we
 will need to seek capital from other sources and risk default under
 the terms of our existing loans. We cannot assure you that
 financing will be available on favorable terms or at all. If we
 fail to obtain substantial cash inflows from existing or new
 partners or other sources prior to November 2016 (or December 2017,
 in the event the prepayment obligations is further extended or
 waived), we could be forced to cease operations. Additionally, if
 additional capital is raised through the sale of equity or
 convertible debt securities, the issuance of such securities would
 result in dilution to our existing stockholders. These conditions
 raise substantial doubt about our ability to continue as a going
 concern. Consequently, the audit reports prepared by our
 independent registered public accounting firm relating to our
 financial statements for the years ended December&amp;#xA0;31, 2015,
 2014 and 2013 include an explanatory paragraph expressing
 substantial doubt about our ability to continue as a going concern.
 Furthermore, despite our optimism regarding the Eligen&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;&amp;#xA0;Technology, even in the event
 that the Company is adequately funded, there is no guarantee that
 any of our partnerships will be successful, that any of our
 products or product candidates will perform as hoped or that such
 products will be successfully commercialized.&lt;/p&gt;


 &lt;/div&gt;</emis:NatureOfOperationsAndLiquidityTextBlock>
  <emis:IncreaseInDebtDiscountForNewDerivatives contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_0D79EF6F-344B-4AD3-ADFC-27ADB3DF6AC0_1_26">2256000</emis:IncreaseInDebtDiscountForNewDerivatives>
  <emis:RevenueRecognitionDisclosureTextBlock contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" id="id_11091862_3B551765-7EAC-4BD2-8350-1E8D18ABCAD3_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;3. Revenue Recognition&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Oral Eligen B12&amp;#x2122; Rx Product&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 We sell our oral Eligen B12&amp;#x2122; Rx product through drug
 wholesalers and retail pharmacies. We recognize revenue from
 prescription product sales, net of sales discounts, chargebacks,
 and rebates. We accept returns of unsalable product from customers
 within a return period of six months prior to and 12 months
 following product expiration. Our oral Eligen B12&amp;#x2122; Rx product
 currently has a shelf life of 24 months from the date of
 manufacture. Given the limited history of our oral Eligen
 B12&amp;#x2122; Rx product, we currently cannot reliably estimate
 expected returns of the prescription products at the time of
 shipment. Accordingly, we will defer recognition of revenue on
 prescription products until the right of return no longer exists,
 which occurs at the earlier of the time the oral Eligen B12&amp;#x2122;
 Rx product is dispensed through patient prescriptions or expiration
 of the right of return.&lt;/p&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Collaborative Agreements and Feasibility Studies&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Revenue earned from collaborative agreements and feasibility
 studies is comprised of reimbursed research and development costs,
 as well as upfront and research and development milestone payments.
 Deferred revenue represents payments received which are related to
 future performance. Revenue from feasibility studies, which are
 typically short term in nature, is recognized upon delivery of the
 study, provided that all other revenue recognition criteria are
 met.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Revenue from collaboration agreements are recognized using the
 proportional performance method provided that we can reasonably
 estimate the level of effort required to complete our performance
 obligations under an arrangement and such performance obligations
 are provided on a best effort basis and based on &amp;#x201C;expected
 payments.&amp;#x201D; Under the proportional performance method,
 periodic revenue related to nonrefundable cash payments is
 recognized as the percentage of actual effort expended to date as
 of that period to the total effort expected for all of our
 performance obligations under the arrangement. Actual effort is
 generally determined based upon actual hours incurred and include
 research and development (&amp;#x201C;R&amp;amp;D&amp;#x201D;) activities
 performed by us and time spent for Joint Steering Committee
 (&amp;#x201C;JSC&amp;#x201D;) activities. Total expected effort is generally
 based upon the total R&amp;amp;D and JSC hours incorporated into the
 project plan that is agreed to by both parties to the
 collaboration. Significant management judgments and estimates are
 required in determining the level of effort required under an
 arrangement and the period over which we expect to complete the
 related performance obligations. Estimates of the total expected
 effort included in each project plan are based on historical
 experience of similar efforts and expectations based on the
 knowledge of scientists for both the Company and its collaboration
 partners. The Company periodically reviews and updates the project
 plan for each collaborative agreement. The most recent reviews took
 place in January 2016. In the event that a change in estimate
 occurs, the change will be accounted for using the cumulative
 catch-up method which provides for an adjustment to revenue in the
 current period. Estimates of our level of effort may change in the
 future, resulting in a material change in the amount of revenue
 recognized in future periods.&lt;/p&gt;
 &lt;p style="font-size:1px;margin-top:12px;margin-bottom:0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Generally, under collaboration arrangements, nonrefundable payments
 received during the period of performance may include time- or
 performance-based milestones. The proportion of actual performance
 to total expected performance is applied to the &amp;#x201C;expected
 payments&amp;#x201D; in determining periodic revenue. However, revenue
 is limited to the sum of (i)&amp;#xA0;the amount of nonrefundable cash
 payments received and (ii)&amp;#xA0;the payments that are contractually
 due but have not yet been paid.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 With regard to revenue recognition in connection with development
 and license agreements that include multiple deliverables,
 Emisphere&amp;#x2019;s management reviews the relevant terms of the
 agreements and determines whether such deliverables should be
 accounted for as a single unit of accounting in accordance with
 FASB ASC 605-25, &lt;i&gt;Multiple-Element Arrangements&lt;/i&gt;. If it is
 determined that a delivered license and Eligen &lt;sup style="font-size:85%; vertical-align:top"&gt;&amp;#xAE;&lt;/sup&gt; Technology do not
 have stand-alone value and Emisphere does not have objective
 evidence of fair value of the undelivered Eligen &lt;sup style="font-size:85%; vertical-align:top"&gt;&amp;#xAE;&lt;/sup&gt; Technology or the
 manufacturing value of all the undelivered items, then such
 deliverables are accounted for as a single unit of accounting and
 any payments received pursuant to such agreement, including any
 upfront or development milestone payments and any payments received
 for support services, will be deferred and included in deferred
 revenue within our balance sheet until such time as management can
 estimate when all of such deliverables will be delivered, if ever.
 Management reviews and reevaluates such conclusions as each item in
 the arrangement is delivered and circumstances of the development
 arrangement change.&lt;/p&gt;
 &lt;/div&gt;</emis:RevenueRecognitionDisclosureTextBlock>
  <emis:CashSweepAsPercentageOfCashProceeds contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" unitRef="pure" decimals="2" id="id_11091862_A66E1C27-E70A-4974-A071-E703602E5FC8_1_3">0.50</emis:CashSweepAsPercentageOfCashProceeds>
  <emis:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAnnualForfeitureRate contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" unitRef="pure" decimals="5" id="id_11091862_64B2D8D8-53A7-4C5C-9FA5-BF51CB9D1299_1_4">0.14523</emis:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAnnualForfeitureRate>
  <emis:DerivativeGainLossOnDerivativeNetRelatedParty contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_3_14">20000</emis:DerivativeGainLossOnDerivativeNetRelatedParty>
  <emis:NoncashInterestExpense contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_0D79EF6F-344B-4AD3-ADFC-27ADB3DF6AC0_1_6">7940000</emis:NoncashInterestExpense>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2021628x2022619" unitRef="shares" decimals="0" id="id_11091862_37AE058B-D22C-4AA0-939A-9CAC5C7BAA0F_1003_600000">6219100</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2021628x2025566" unitRef="shares" decimals="0" id="id_11091862_37AE058B-D22C-4AA0-939A-9CAC5C7BAA0F_2003_600002">45824469</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2021628x2039180" unitRef="shares" decimals="0" id="id_11091862_37AE058B-D22C-4AA0-939A-9CAC5C7BAA0F_3003_600001">21997775</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2026671x2101271_2037554x2027084" unitRef="shares" decimals="INF" id="id_11091862_D41D4163-C5C5-40F7-805C-4C1353BAB1CF_1001_0">40000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <emis:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValuePerShare contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2026671x2101271_2037554x2027084" unitRef="iso4217_USD_per_shares" decimals="2" id="id_11091862_D41D4163-C5C5-40F7-805C-4C1353BAB1CF_1001_1">0.61</emis:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValuePerShare>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2026703x2108947" id="id_11091862_14A5142A-C3D0-4778-9EDC-9DD8F18F9487_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 The assumptions used in computing the fair value of the Amended and
 Restated June 2010 Warrants as of September&amp;#xA0;30, 2016 and
 December&amp;#xA0;31, 2015, are as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Closing stock price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.70&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.68&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Conversion price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;107&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;136&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Remaining term (years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.77&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.52&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Risk-free rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.85&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.42&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2026703x2108947" unitRef="pure" decimals="2" id="id_11091862_93C457E5-E443-4587-8859-653E17C5367A_1001_5">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2026703x2108947" unitRef="iso4217_USD" decimals="-5" id="id_11091862_3BB9028A-D3F1-40A2-97C3-73C4325334EB_2_1">-100000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2026703x2108947" unitRef="pure" decimals="2" id="id_11091862_93C457E5-E443-4587-8859-653E17C5367A_1001_2">1.07</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2026703x2108947" unitRef="pure" decimals="4" id="id_11091862_93C457E5-E443-4587-8859-653E17C5367A_1001_4">0.0085</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <emis:RemainingTermOfExpectedVolatility contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2026703x2108947" id="id_11091862_93C457E5-E443-4587-8859-653E17C5367A_1001_3">P2Y9M7D</emis:RemainingTermOfExpectedVolatility>
  <emis:ReducedExercisePriceOfWarrants contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2026703x2108947" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11091862_64D9B9EB-F454-4AB4-A220-CC34112B0ED7_1001_2">0.50</emis:ReducedExercisePriceOfWarrants>
  <emis:WarrantsExpiryDate contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2026703x2108947" id="id_11091862_64D9B9EB-F454-4AB4-A220-CC34112B0ED7_1001_3">2019-07-08</emis:WarrantsExpiryDate>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2026703x2116523" id="id_11091862_0D91E7D1-70F5-48D8-A8A0-F08899AC3EFF_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The assumptions used in computing the fair values as
 September&amp;#xA0;30, 2016 and December&amp;#xA0;31, 2015, are as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Closing stock price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.70&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.68&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Conversion price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.25&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.25&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;146&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;143&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Remaining term (years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.25&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Risk-free rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.20&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.95&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2026703x2116523" unitRef="pure" decimals="2" id="id_11091862_79F87DD4-E654-41A8-B3DC-AA1B3FDEEFB1_1001_5">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2026703x2116523" unitRef="iso4217_USD" decimals="-5" id="id_11091862_1077132B-728C-4E28-BBB4-89785F981CDD_1002_0">1500000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2026703x2116523" unitRef="pure" decimals="2" id="id_11091862_79F87DD4-E654-41A8-B3DC-AA1B3FDEEFB1_1001_2">1.46</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2026703x2116523" unitRef="pure" decimals="4" id="id_11091862_79F87DD4-E654-41A8-B3DC-AA1B3FDEEFB1_1001_4">0.0120</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <emis:RemainingTermOfExpectedVolatility contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2026703x2116523" id="id_11091862_79F87DD4-E654-41A8-B3DC-AA1B3FDEEFB1_1001_3">P5Y6M</emis:RemainingTermOfExpectedVolatility>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2026703x2169752" id="id_11091862_1EC834BA-6671-4A01-9446-8D8DE9B4D8DD_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The assumptions used in computing the fair value as of
 September&amp;#xA0;30, 2016 and December&amp;#xA0;31, 2015 are as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;br /&gt;
 2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Closing stock price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.70&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.68&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Conversion price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;146&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;143&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Remaining term (years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.25&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Risk-free rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.20&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.95&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2026703x2169752" unitRef="pure" decimals="2" id="id_11091862_5AE60755-3FF9-4D29-93AF-65E82E0A2BE1_1001_5">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2026703x2169752" unitRef="iso4217_USD" decimals="-5" id="id_11091862_D885EB1C-2C37-42C2-82A3-7D63CDB2564C_1002_0">400000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2026703x2169752" unitRef="pure" decimals="2" id="id_11091862_5AE60755-3FF9-4D29-93AF-65E82E0A2BE1_1001_2">1.46</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2026703x2169752" unitRef="pure" decimals="4" id="id_11091862_5AE60755-3FF9-4D29-93AF-65E82E0A2BE1_1001_4">0.0120</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <emis:RemainingTermOfExpectedVolatility contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2026703x2169752" id="id_11091862_5AE60755-3FF9-4D29-93AF-65E82E0A2BE1_1001_3">P5Y6M</emis:RemainingTermOfExpectedVolatility>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2026703x2175516" id="id_11091862_3DAED5A8-7B40-4ABC-B94B-C000B9E9848E_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The assumptions used in computing the fair value as of
 September&amp;#xA0;30, 2016 and December&amp;#xA0;31, 2015 are as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Closing stock price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.70&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.68&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Conversion price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;146&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;143&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Remaining term (years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.25&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Risk-free rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.20&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.95&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2026703x2175516" unitRef="pure" decimals="2" id="id_11091862_8969B07E-C46D-45F3-908B-F6C2E13F35D2_1001_5">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2026703x2175516" unitRef="iso4217_USD" decimals="-5" id="id_11091862_5719D650-B037-4B9C-B244-C007093509EE_1002_500000">200000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2026703x2175516" unitRef="pure" decimals="2" id="id_11091862_8969B07E-C46D-45F3-908B-F6C2E13F35D2_1001_2">1.46</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2026703x2175516" unitRef="pure" decimals="4" id="id_11091862_8969B07E-C46D-45F3-908B-F6C2E13F35D2_1001_4">0.0120</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <emis:RemainingTermOfExpectedVolatility contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2026703x2175516" id="id_11091862_8969B07E-C46D-45F3-908B-F6C2E13F35D2_1001_3">P5Y6M</emis:RemainingTermOfExpectedVolatility>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2026703x2206022" id="id_11091862_0A96A51D-77E2-45E7-8632-C9410AFEBAD4_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 The assumptions used in computing the fair value of the 2013
 Restructuring Warrants as of September&amp;#xA0;30, 2016 and
 December&amp;#xA0;31, 2015, are as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Closing stock price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.70&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.68&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Conversion price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;107&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;141&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Remaining term (years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.77&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.52&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Risk-free rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.88&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.31&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2026703x2206022" unitRef="pure" decimals="2" id="id_11091862_1B565D30-961F-45EF-860C-A4134428CFAB_1001_5">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2026703x2206022" unitRef="pure" decimals="2" id="id_11091862_1B565D30-961F-45EF-860C-A4134428CFAB_1001_2">1.07</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2026703x2206022" unitRef="pure" decimals="4" id="id_11091862_1B565D30-961F-45EF-860C-A4134428CFAB_1001_4">0.0088</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <emis:RemainingTermOfExpectedVolatility contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2026703x2206022" id="id_11091862_1B565D30-961F-45EF-860C-A4134428CFAB_1001_3">P2Y9M7D</emis:RemainingTermOfExpectedVolatility>
  <emis:FairValueOfWarrantsDecreased contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2026703x2206022" unitRef="iso4217_USD" decimals="-5" id="id_11091862_0149DF0A-F4B8-4CC9-97F5-74759753791D_1002_0">900000</emis:FairValueOfWarrantsDecreased>
  <emis:WarrantsExpiryDate contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2026703x2239968" id="id_11091862_191DD95B-41F9-43FF-BCDF-56AD8646B3C7_1001_2">2015-08-26</emis:WarrantsExpiryDate>
  <emis:FairValueOfWarrantsDecreased contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2026703x2350711" unitRef="iso4217_USD" decimals="-5" id="id_11091862_2390537A-25F6-4790-9DC9-46689BFF2ABA_1001_0">200000</emis:FairValueOfWarrantsDecreased>
  <emis:NumberOfWarrantsSoldToFund contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2026703x2350711" unitRef="shares" decimals="-4" id="id_11091862_27EB674B-455A-4D23-8DC5-CBCB67BAA360_1_0">3010000</emis:NumberOfWarrantsSoldToFund>
  <emis:WarrantsExpiryDate contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2026703x2350711" id="id_11091862_27EB674B-455A-4D23-8DC5-CBCB67BAA360_1_1">2016-07-06</emis:WarrantsExpiryDate>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2026789x2039180" id="id_11091862_AA2699FC-7A91-4FA9-9108-ABC9A73B0037_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The assumptions used in computing the fair value of the Original
 Warrants as of September&amp;#xA0;30, 2016 and December&amp;#xA0;31, 2015,
 are as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Closing stock price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.70&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.68&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Conversion price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;107&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;141&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Remaining term (years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.77&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.52&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Risk-free rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.88&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.31&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2026789x2039180" unitRef="pure" decimals="2" id="id_11091862_4D8346E3-44CA-4F59-A3FF-80B8D16AA009_1001_5">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2026789x2039180" unitRef="iso4217_USD" decimals="-5" id="id_11091862_FA0EDE69-0B47-420F-A4A4-436907E12EFC_1002_1">-1000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2026789x2039180" unitRef="pure" decimals="2" id="id_11091862_4D8346E3-44CA-4F59-A3FF-80B8D16AA009_1001_2">1.07</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2026789x2039180" unitRef="pure" decimals="4" id="id_11091862_4D8346E3-44CA-4F59-A3FF-80B8D16AA009_1001_4">0.0088</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <emis:RemainingTermOfExpectedVolatility contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2026789x2039180" id="id_11091862_4D8346E3-44CA-4F59-A3FF-80B8D16AA009_1001_3">P2Y9M7D</emis:RemainingTermOfExpectedVolatility>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2027723x2116523" unitRef="shares" decimals="INF" id="id_11091862_F3204A84-6102-4622-B13F-1423E77D0E6A_1001_3">39720243</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <us-gaap:DebtInstrumentMaturityDate contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2027723x2116523" id="id_11091862_02836261-D58A-47B4-ADB3-D1CE86585ED8_1001_0">2022-03-31</us-gaap:DebtInstrumentMaturityDate>
  <emis:AdjustedFreeCashFlowIncome contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2027723x2116523" unitRef="iso4217_USD" decimals="-6" id="id_11091862_02836261-D58A-47B4-ADB3-D1CE86585ED8_1001_4">50000000</emis:AdjustedFreeCashFlowIncome>
  <emis:CashSweepAsPercentageOfConsolidatedFreeCashFlow contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2027723x2116523" unitRef="pure" decimals="2" id="id_11091862_02836261-D58A-47B4-ADB3-D1CE86585ED8_1001_2">0.50</emis:CashSweepAsPercentageOfConsolidatedFreeCashFlow>
  <emis:CashSweepAsPercentageOfCashProceeds contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2027723x2116523" unitRef="pure" decimals="2" id="id_11091862_F3204A84-6102-4622-B13F-1423E77D0E6A_1001_1">0.50</emis:CashSweepAsPercentageOfCashProceeds>
  <emis:RoyaltyAgreementDate contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2027749x2037322" id="id_11091862_0717E65F-F15A-40EB-B389-CCA55985153F_1001_0">2014-08-20</emis:RoyaltyAgreementDate>
  <emis:RoyaltyTermDescription contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2027749x2037322" id="id_11091862_7B32B99A-9B36-4AC1-ACFD-0269AD310592_1001_3">(i) five percent (5%) of all Net Sales and third party payments commencing with the first quarter immediately following the quarter in which the Indebtedness Repayment Condition is satisfied, or (ii) two and one half percent (2.5%) of all Net Sales commencing with the quarter immediately following the quarter in which the Indebtedness Repayment Condition is satisfied, but only with respect to the Net Sales made in any country in which there was not a Valid Patent Claim (as defined in the Royalty Agreement) and where generic entry of a competitive product not by the Company or its affiliates that does not infringe a Valid Patent Claim in such country has occurred, in each case as of the last day of such Fiscal Quarter.</emis:RoyaltyTermDescription>
  <emis:PeriodOfProductReturnAfterExpiration contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2028497x2030148" id="id_11091862_671556E7-8220-46AC-9CAF-CBF8D01DD5B4_1_0">P6M</emis:PeriodOfProductReturnAfterExpiration>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2028497x2030148_2030037x2023509" id="id_11091862_B1CC4165-0EE6-48F1-901E-A0A761E5C430_1001_0">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <emis:WaiverPeriodToPrepayCertainLoansAndNotes contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2028497x2033371" id="id_11091862_9B4243B3-6795-41E1-9248-5A0AEED89DD3_1002_1">P1Y</emis:WaiverPeriodToPrepayCertainLoansAndNotes>
  <emis:PeriodToPrepayCertainLoansAndNotes contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2028497x2033371" id="id_11091862_A7C548DA-F454-489D-8B93-AF7538DD139E_1003_3">P1Y</emis:PeriodToPrepayCertainLoansAndNotes>
  <emis:PeriodOfProductReturnAfterExpiration contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2028497x2033371" id="id_11091862_671556E7-8220-46AC-9CAF-CBF8D01DD5B4_2_0">P12M</emis:PeriodOfProductReturnAfterExpiration>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2028497x2033371_2030037x2023509" id="id_11091862_B1CC4165-0EE6-48F1-901E-A0A761E5C430_1002_0">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <emis:PropertyPlantAndEquipmentLife contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2030037x2024220" id="id_11091862_B1CC4165-0EE6-48F1-901E-A0A761E5C430_2003_1">Term of lease</emis:PropertyPlantAndEquipmentLife>
  <us-gaap:RestructuringAndRelatedActivitiesInitiationDate contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2033594x2118616" id="id_11091862_B111426F-A1E7-4640-BA8D-14B9644EDCD4_1001_1">2013-05-07</us-gaap:RestructuringAndRelatedActivitiesInitiationDate>
  <emis:DebtInstrumentAdditionalInterestRateStatedPercentageRate contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2033594x2118616" unitRef="pure" decimals="INF" id="id_11091862_2796B579-1B6E-4E17-A7B9-C4E71EF7D169_1001_1">0.02</emis:DebtInstrumentAdditionalInterestRateStatedPercentageRate>
  <us-gaap:DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2033594x2169752" id="id_11091862_814EA120-3706-476B-A6DF-7AD4BCE88C96_1002_2">The Bridge Notes were amended and restated on May 7, 2013 and restated  again on August 20, 2014.</us-gaap:DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault>
  <us-gaap:DebtInstrumentInterestRateTerms contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2033594x2169752" id="id_11091862_92DA53DE-184C-4636-97A6-B8F4943C8289_1001_2">Interest at 13% per year, compounded monthly and payable in the form of  additional Bridge Notes.</us-gaap:DebtInstrumentInterestRateTerms>
  <us-gaap:DebtInstrumentMaturityDate contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2033594x2169752" id="id_11091862_92DA53DE-184C-4636-97A6-B8F4943C8289_1001_0">2022-03-31</us-gaap:DebtInstrumentMaturityDate>
  <emis:CashSweepAsPercentageOfConsolidatedFreeCashFlow contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2033594x2169752" unitRef="pure" decimals="2" id="id_11091862_92DA53DE-184C-4636-97A6-B8F4943C8289_1001_3">0.50</emis:CashSweepAsPercentageOfConsolidatedFreeCashFlow>
  <emis:DebtInstrumentConvertibleAmendedConversionPrice contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2033594x2169752" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11091862_92DA53DE-184C-4636-97A6-B8F4943C8289_1001_4">0.50</emis:DebtInstrumentConvertibleAmendedConversionPrice>
  <us-gaap:DebtInstrumentInterestRateTerms contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2033594x2175516" id="id_11091862_B2EFE399-6D8B-46FF-930E-ACD8F62F3C8A_1001_2">Interest at the rate of 10% per annum, compounded monthly,  which interest is payable in the form of additional Reimbursement Notes.</us-gaap:DebtInstrumentInterestRateTerms>
  <us-gaap:DebtInstrumentMaturityDate contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2033594x2175516" id="id_11091862_B2EFE399-6D8B-46FF-930E-ACD8F62F3C8A_1001_0">2022-03-31</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:RestructuringAndRelatedActivitiesInitiationDate contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2033594x2175516" id="id_11091862_B111426F-A1E7-4640-BA8D-14B9644EDCD4_2001_2">2014-08-20</us-gaap:RestructuringAndRelatedActivitiesInitiationDate>
  <emis:CashSweepAsPercentageOfConsolidatedFreeCashFlow contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2033594x2175516" unitRef="pure" decimals="2" id="id_11091862_B2EFE399-6D8B-46FF-930E-ACD8F62F3C8A_1001_4">0.50</emis:CashSweepAsPercentageOfConsolidatedFreeCashFlow>
  <us-gaap:DebtInstrumentMaturityDate contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2033594x2335086" id="id_11091862_8B361D9A-C327-4910-8F26-A0A46F8A854B_1001_1">2019-12-31</us-gaap:DebtInstrumentMaturityDate>
  <emis:CashSweepAsPercentageOfConsolidatedFreeCashFlow contextRef="eol_PE5372----1610-Q0007_STD_274_20160930_0_2033594x2335086" unitRef="pure" decimals="2" id="id_11091862_A66E1C27-E70A-4974-A071-E703602E5FC8_1001_0">0.50</emis:CashSweepAsPercentageOfConsolidatedFreeCashFlow>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease contextRef="eol_PE5372----1610-Q0007_STD_359_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_D29FE026-1599-4403-9062-97F6F4B06410_2_4">7079000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="eol_PE5372----1610-Q0007_STD_359_20151231_0_2026703x2108947" unitRef="pure" decimals="2" id="id_11091862_93C457E5-E443-4587-8859-653E17C5367A_1002_5">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE5372----1610-Q0007_STD_359_20151231_0_2026703x2108947" unitRef="pure" decimals="2" id="id_11091862_93C457E5-E443-4587-8859-653E17C5367A_1002_2">1.36</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE5372----1610-Q0007_STD_359_20151231_0_2026703x2108947" unitRef="pure" decimals="4" id="id_11091862_93C457E5-E443-4587-8859-653E17C5367A_1002_4">0.0142</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <emis:RemainingTermOfExpectedVolatility contextRef="eol_PE5372----1610-Q0007_STD_359_20151231_0_2026703x2108947" id="id_11091862_93C457E5-E443-4587-8859-653E17C5367A_1002_3">P3Y6M7D</emis:RemainingTermOfExpectedVolatility>
  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="eol_PE5372----1610-Q0007_STD_359_20151231_0_2026703x2116523" unitRef="pure" decimals="2" id="id_11091862_79F87DD4-E654-41A8-B3DC-AA1B3FDEEFB1_1002_5">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE5372----1610-Q0007_STD_359_20151231_0_2026703x2116523" unitRef="pure" decimals="2" id="id_11091862_79F87DD4-E654-41A8-B3DC-AA1B3FDEEFB1_1002_2">1.43</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE5372----1610-Q0007_STD_359_20151231_0_2026703x2116523" unitRef="pure" decimals="4" id="id_11091862_79F87DD4-E654-41A8-B3DC-AA1B3FDEEFB1_1002_4">0.0195</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <emis:RemainingTermOfExpectedVolatility contextRef="eol_PE5372----1610-Q0007_STD_359_20151231_0_2026703x2116523" id="id_11091862_79F87DD4-E654-41A8-B3DC-AA1B3FDEEFB1_1002_3">P6Y3M</emis:RemainingTermOfExpectedVolatility>
  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="eol_PE5372----1610-Q0007_STD_359_20151231_0_2026703x2169752" unitRef="pure" decimals="2" id="id_11091862_5AE60755-3FF9-4D29-93AF-65E82E0A2BE1_1002_5">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE5372----1610-Q0007_STD_359_20151231_0_2026703x2169752" unitRef="pure" decimals="2" id="id_11091862_5AE60755-3FF9-4D29-93AF-65E82E0A2BE1_1002_2">1.43</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE5372----1610-Q0007_STD_359_20151231_0_2026703x2169752" unitRef="pure" decimals="4" id="id_11091862_5AE60755-3FF9-4D29-93AF-65E82E0A2BE1_1002_4">0.0195</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <emis:RemainingTermOfExpectedVolatility contextRef="eol_PE5372----1610-Q0007_STD_359_20151231_0_2026703x2169752" id="id_11091862_5AE60755-3FF9-4D29-93AF-65E82E0A2BE1_1002_3">P6Y3M</emis:RemainingTermOfExpectedVolatility>
  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="eol_PE5372----1610-Q0007_STD_359_20151231_0_2026703x2175516" unitRef="pure" decimals="2" id="id_11091862_8969B07E-C46D-45F3-908B-F6C2E13F35D2_1002_5">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE5372----1610-Q0007_STD_359_20151231_0_2026703x2175516" unitRef="pure" decimals="2" id="id_11091862_8969B07E-C46D-45F3-908B-F6C2E13F35D2_1002_2">1.43</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE5372----1610-Q0007_STD_359_20151231_0_2026703x2175516" unitRef="pure" decimals="4" id="id_11091862_8969B07E-C46D-45F3-908B-F6C2E13F35D2_1002_4">0.0195</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <emis:RemainingTermOfExpectedVolatility contextRef="eol_PE5372----1610-Q0007_STD_359_20151231_0_2026703x2175516" id="id_11091862_8969B07E-C46D-45F3-908B-F6C2E13F35D2_1002_3">P6Y3M</emis:RemainingTermOfExpectedVolatility>
  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="eol_PE5372----1610-Q0007_STD_359_20151231_0_2026703x2206022" unitRef="pure" decimals="2" id="id_11091862_1B565D30-961F-45EF-860C-A4134428CFAB_1002_5">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE5372----1610-Q0007_STD_359_20151231_0_2026703x2206022" unitRef="pure" decimals="2" id="id_11091862_1B565D30-961F-45EF-860C-A4134428CFAB_1002_2">1.41</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE5372----1610-Q0007_STD_359_20151231_0_2026703x2206022" unitRef="pure" decimals="4" id="id_11091862_1B565D30-961F-45EF-860C-A4134428CFAB_1002_4">0.0131</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <emis:RemainingTermOfExpectedVolatility contextRef="eol_PE5372----1610-Q0007_STD_359_20151231_0_2026703x2206022" id="id_11091862_1B565D30-961F-45EF-860C-A4134428CFAB_1002_3">P3Y6M7D</emis:RemainingTermOfExpectedVolatility>
  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="eol_PE5372----1610-Q0007_STD_359_20151231_0_2026789x2039180" unitRef="pure" decimals="2" id="id_11091862_4D8346E3-44CA-4F59-A3FF-80B8D16AA009_1002_5">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE5372----1610-Q0007_STD_359_20151231_0_2026789x2039180" unitRef="pure" decimals="2" id="id_11091862_4D8346E3-44CA-4F59-A3FF-80B8D16AA009_1002_2">1.41</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE5372----1610-Q0007_STD_359_20151231_0_2026789x2039180" unitRef="pure" decimals="4" id="id_11091862_4D8346E3-44CA-4F59-A3FF-80B8D16AA009_1002_4">0.0131</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <emis:RemainingTermOfExpectedVolatility contextRef="eol_PE5372----1610-Q0007_STD_359_20151231_0_2026789x2039180" id="id_11091862_4D8346E3-44CA-4F59-A3FF-80B8D16AA009_1002_3">P3Y6M7D</emis:RemainingTermOfExpectedVolatility>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE5372----1610-Q0007_STD_91_20150930_0" unitRef="shares" decimals="0" id="id_11091862_37AE058B-D22C-4AA0-939A-9CAC5C7BAA0F_2_500003">8896702</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE5372----1610-Q0007_STD_91_20150930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_2_19">-0.07</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE5372----1610-Q0007_STD_91_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_2_6">1352000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:DepreciationAndAmortization contextRef="eol_PE5372----1610-Q0007_STD_91_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_2_8">3000</us-gaap:DepreciationAndAmortization>
  <us-gaap:CostOfGoodsSold contextRef="eol_PE5372----1610-Q0007_STD_91_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_2_1">58000</us-gaap:CostOfGoodsSold>
  <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet contextRef="eol_PE5372----1610-Q0007_STD_91_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_2_15">232000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
  <us-gaap:Revenues contextRef="eol_PE5372----1610-Q0007_STD_91_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_2_0">130000</us-gaap:Revenues>
  <us-gaap:InterestExpenseRelatedParty contextRef="eol_PE5372----1610-Q0007_STD_91_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_2_16">2321000</us-gaap:InterestExpenseRelatedParty>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE5372----1610-Q0007_STD_91_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_2_17">246000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE5372----1610-Q0007_STD_91_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_2_12">1000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:GrossProfit contextRef="eol_PE5372----1610-Q0007_STD_91_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_2_3">72000</us-gaap:GrossProfit>
  <us-gaap:OperatingExpenses contextRef="eol_PE5372----1610-Q0007_STD_91_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_2_9">4740000</us-gaap:OperatingExpenses>
  <us-gaap:NetIncomeLoss contextRef="eol_PE5372----1610-Q0007_STD_91_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_2_18">-4422000</us-gaap:NetIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE5372----1610-Q0007_STD_91_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_2_10">-4668000</us-gaap:OperatingIncomeLoss>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE5372----1610-Q0007_STD_91_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_2_5">94000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:SellingAndMarketingExpense contextRef="eol_PE5372----1610-Q0007_STD_91_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_2_7">3291000</us-gaap:SellingAndMarketingExpense>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE5372----1610-Q0007_STD_91_20150930_0" unitRef="shares" decimals="0" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_2_20">60687478</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <emis:DerivativeGainLossOnDerivativeNetRelatedParty contextRef="eol_PE5372----1610-Q0007_STD_91_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_2_14">2334000</emis:DerivativeGainLossOnDerivativeNetRelatedParty>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE5372----1610-Q0007_STD_91_20150930_0_2021628x2022619" unitRef="shares" decimals="0" id="id_11091862_37AE058B-D22C-4AA0-939A-9CAC5C7BAA0F_1002_500000">6390750</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE5372----1610-Q0007_STD_91_20150930_0_2021628x2025566" unitRef="shares" decimals="0" id="id_11091862_37AE058B-D22C-4AA0-939A-9CAC5C7BAA0F_2002_500002">40297635</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE5372----1610-Q0007_STD_91_20150930_0_2021628x2039180" unitRef="shares" decimals="0" id="id_11091862_37AE058B-D22C-4AA0-939A-9CAC5C7BAA0F_3002_500001">25008082</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="eol_PE5372----1610-Q0007_STD_91_20150930_0_2026703x2108947" unitRef="iso4217_USD" decimals="-3" id="id_11091862_3BB9028A-D3F1-40A2-97C3-73C4325334EB_3_0">-60000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="eol_PE5372----1610-Q0007_STD_91_20150930_0_2026703x2116523" unitRef="iso4217_USD" decimals="-5" id="id_11091862_1077132B-728C-4E28-BBB4-89785F981CDD_1003_0">-300000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="eol_PE5372----1610-Q0007_STD_91_20150930_0_2026703x2169752" unitRef="iso4217_USD" decimals="-5" id="id_11091862_D885EB1C-2C37-42C2-82A3-7D63CDB2564C_1003_0">-100000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="eol_PE5372----1610-Q0007_STD_91_20150930_0_2026703x2175516" unitRef="iso4217_USD" decimals="-2" id="id_11091862_5719D650-B037-4B9C-B244-C007093509EE_1003_600000">-33000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
  <emis:FairValueOfWarrantsDecreased contextRef="eol_PE5372----1610-Q0007_STD_91_20150930_0_2026703x2206022" unitRef="iso4217_USD" decimals="-5" id="id_11091862_0149DF0A-F4B8-4CC9-97F5-74759753791D_1003_0">900000</emis:FairValueOfWarrantsDecreased>
  <emis:FairValueOfWarrantsDecreased contextRef="eol_PE5372----1610-Q0007_STD_91_20150930_0_2026703x2239968" unitRef="iso4217_USD" decimals="-3" id="id_11091862_CE8724AD-AF00-4BA0-9B47-A14D33B96176_1001_0">15000</emis:FairValueOfWarrantsDecreased>
  <emis:FairValueOfWarrantsDecreased contextRef="eol_PE5372----1610-Q0007_STD_91_20150930_0_2026703x2350711" unitRef="iso4217_USD" decimals="-5" id="id_11091862_2390537A-25F6-4790-9DC9-46689BFF2ABA_1002_0">200000</emis:FairValueOfWarrantsDecreased>
  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="eol_PE5372----1610-Q0007_STD_91_20150930_0_2026789x2039180" unitRef="iso4217_USD" decimals="-5" id="id_11091862_FA0EDE69-0B47-420F-A4A4-436907E12EFC_1003_1">-1000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE5372----1610-Q0007_STD_92_20160930_0" unitRef="shares" decimals="0" id="id_11091862_37AE058B-D22C-4AA0-939A-9CAC5C7BAA0F_1_400003">77051651</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE5372----1610-Q0007_STD_92_20160930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_1_19">-0.09</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE5372----1610-Q0007_STD_92_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_15EBE9C9-8CD6-404A-96F6-0E36F0106F18_3_0">80000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE5372----1610-Q0007_STD_92_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_1_6">1381000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:DepreciationAndAmortization contextRef="eol_PE5372----1610-Q0007_STD_92_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_1_8">3000</us-gaap:DepreciationAndAmortization>
  <us-gaap:CostOfGoodsSold contextRef="eol_PE5372----1610-Q0007_STD_92_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_1_1">41000</us-gaap:CostOfGoodsSold>
  <us-gaap:Revenues contextRef="eol_PE5372----1610-Q0007_STD_92_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_1_0">204000</us-gaap:Revenues>
  <us-gaap:InterestExpenseRelatedParty contextRef="eol_PE5372----1610-Q0007_STD_92_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_1_16">2772000</us-gaap:InterestExpenseRelatedParty>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE5372----1610-Q0007_STD_92_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_1_17">-3205000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE5372----1610-Q0007_STD_92_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_1_12">3000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:GrossProfit contextRef="eol_PE5372----1610-Q0007_STD_92_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_1_3">-397000</us-gaap:GrossProfit>
  <us-gaap:OperatingExpenses contextRef="eol_PE5372----1610-Q0007_STD_92_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_1_9">1601000</us-gaap:OperatingExpenses>
  <us-gaap:NetIncomeLoss contextRef="eol_PE5372----1610-Q0007_STD_92_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_1_18">-5203000</us-gaap:NetIncomeLoss>
  <us-gaap:InventoryWriteDown contextRef="eol_PE5372----1610-Q0007_STD_92_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_1_2">560000</us-gaap:InventoryWriteDown>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE5372----1610-Q0007_STD_92_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_1_10">-1998000</us-gaap:OperatingIncomeLoss>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE5372----1610-Q0007_STD_92_20160930_0" unitRef="shares" decimals="INF" id="id_11091862_15EBE9C9-8CD6-404A-96F6-0E36F0106F18_3_3">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:RoyaltyExpense contextRef="eol_PE5372----1610-Q0007_STD_92_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_512FF41A-3593-42B5-AA28-786968DFF670_1_0">32000</us-gaap:RoyaltyExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE5372----1610-Q0007_STD_92_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_1_5">80000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:SellingAndMarketingExpense contextRef="eol_PE5372----1610-Q0007_STD_92_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_1_7">137000</us-gaap:SellingAndMarketingExpense>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE5372----1610-Q0007_STD_92_20160930_0" unitRef="shares" decimals="0" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_1_20">60687478</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <emis:DerivativeGainLossOnDerivativeNetRelatedParty contextRef="eol_PE5372----1610-Q0007_STD_92_20160930_0" unitRef="iso4217_USD" decimals="-3" id="id_11091862_055A456B-A933-4395-85BA-28BFE3A70DB6_1_14">-436000</emis:DerivativeGainLossOnDerivativeNetRelatedParty>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE5372----1610-Q0007_STD_92_20160930_0_2021628x2022619" unitRef="shares" decimals="0" id="id_11091862_37AE058B-D22C-4AA0-939A-9CAC5C7BAA0F_1001_400000">6219100</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE5372----1610-Q0007_STD_92_20160930_0_2021628x2025566" unitRef="shares" decimals="0" id="id_11091862_37AE058B-D22C-4AA0-939A-9CAC5C7BAA0F_2001_400002">45824469</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE5372----1610-Q0007_STD_92_20160930_0_2021628x2039180" unitRef="shares" decimals="0" id="id_11091862_37AE058B-D22C-4AA0-939A-9CAC5C7BAA0F_3001_400001">21997775</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="eol_PE5372----1610-Q0007_STD_92_20160930_0_2026703x2108947" unitRef="iso4217_USD" decimals="-3" id="id_11091862_3BB9028A-D3F1-40A2-97C3-73C4325334EB_1_0">-15000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="eol_PE5372----1610-Q0007_STD_92_20160930_0_2026703x2116523" unitRef="iso4217_USD" decimals="-5" id="id_11091862_1077132B-728C-4E28-BBB4-89785F981CDD_1001_0">600000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="eol_PE5372----1610-Q0007_STD_92_20160930_0_2026703x2169752" unitRef="iso4217_USD" decimals="-5" id="id_11091862_D885EB1C-2C37-42C2-82A3-7D63CDB2564C_1001_0">100000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="eol_PE5372----1610-Q0007_STD_92_20160930_0_2026703x2175516" unitRef="iso4217_USD" decimals="-2" id="id_11091862_5719D650-B037-4B9C-B244-C007093509EE_1001_400000">35000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
  <emis:FairValueOfWarrantsDecreased contextRef="eol_PE5372----1610-Q0007_STD_92_20160930_0_2026703x2206022" unitRef="iso4217_USD" decimals="-5" id="id_11091862_0149DF0A-F4B8-4CC9-97F5-74759753791D_1001_0">100000</emis:FairValueOfWarrantsDecreased>
  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="eol_PE5372----1610-Q0007_STD_92_20160930_0_2026789x2039180" unitRef="iso4217_USD" decimals="-5" id="id_11091862_FA0EDE69-0B47-420F-A4A4-436907E12EFC_1001_0">-200000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
  <context id="eol_PE5372----1610-Q0007_STD_92_20160930_0_2026789x2039180">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-07-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_92_20160930_0_2026703x2206022">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:TwoThousandAndThirteenRestructuringWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-07-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_92_20160930_0_2026703x2175516">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:ReimbursementNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-07-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_92_20160930_0_2026703x2169752">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:BridgeNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-07-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_92_20160930_0_2026703x2116523">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:ConvertibleNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-07-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_92_20160930_0_2026703x2108947">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:AmendedAndRestatedJuneTwoThousandAndTenWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-07-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_92_20160930_0_2021628x2039180">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-07-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_92_20160930_0_2021628x2025566">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-07-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_92_20160930_0_2021628x2022619">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-07-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_92_20160930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
    </entity>
    <period>
      <startDate>2016-07-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_91_20150930_0_2026789x2039180">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-07-02</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_91_20150930_0_2026703x2350711">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:JulyTwoThousandAndElevenInvestorWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-07-02</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_91_20150930_0_2026703x2239968">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:AugustTwoThousandAndTenWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-07-02</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_91_20150930_0_2026703x2206022">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:TwoThousandAndThirteenRestructuringWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-07-02</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_91_20150930_0_2026703x2175516">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:ReimbursementNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-07-02</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_91_20150930_0_2026703x2169752">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:BridgeNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-07-02</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_91_20150930_0_2026703x2116523">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:ConvertibleNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-07-02</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_91_20150930_0_2026703x2108947">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:AmendedAndRestatedJuneTwoThousandAndTenWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-07-02</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_91_20150930_0_2021628x2039180">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-07-02</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_91_20150930_0_2021628x2025566">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-07-02</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_91_20150930_0_2021628x2022619">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-07-02</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_91_20150930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
    </entity>
    <period>
      <startDate>2015-07-02</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_359_20151231_0_2026789x2039180">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-07</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_359_20151231_0_2026703x2206022">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:TwoThousandAndThirteenRestructuringWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-07</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_359_20151231_0_2026703x2175516">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:ReimbursementNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-07</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_359_20151231_0_2026703x2169752">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:BridgeNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-07</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_359_20151231_0_2026703x2116523">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:ConvertibleNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-07</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_359_20151231_0_2026703x2108947">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:AmendedAndRestatedJuneTwoThousandAndTenWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-07</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_359_20151231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
    </entity>
    <period>
      <startDate>2015-01-07</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_274_20160930_0_2033594x2335086">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">emis:LoanAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_274_20160930_0_2033594x2175516">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">emis:ReimbursementNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_274_20160930_0_2033594x2169752">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">emis:BridgeNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_274_20160930_0_2033594x2118616">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">emis:MHRPromissoryNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_274_20160930_0_2030037x2024220">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetsHeldUnderCapitalLeasesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_274_20160930_0_2028497x2033371_2030037x2023509">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_274_20160930_0_2028497x2033371">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_274_20160930_0_2028497x2030148_2030037x2023509">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_274_20160930_0_2028497x2030148">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_274_20160930_0_2027749x2037322">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:RoyaltyArrangementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_274_20160930_0_2027723x2116523">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">emis:ConvertibleNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_274_20160930_0_2026789x2039180">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_274_20160930_0_2026703x2350711">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:JulyTwoThousandAndElevenInvestorWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_274_20160930_0_2026703x2239968">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:AugustTwoThousandAndTenWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_274_20160930_0_2026703x2206022">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:TwoThousandAndThirteenRestructuringWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_274_20160930_0_2026703x2175516">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:ReimbursementNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_274_20160930_0_2026703x2169752">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:BridgeNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_274_20160930_0_2026703x2116523">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:ConvertibleNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_274_20160930_0_2026703x2108947">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:AmendedAndRestatedJuneTwoThousandAndTenWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_274_20160930_0_2026671x2101271_2037554x2027084">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis">emis:BlackScholesOptionPricingModelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefFinancialOfficerMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_274_20160930_0_2021628x2039180">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_274_20160930_0_2021628x2025566">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_274_20160930_0_2021628x2022619">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_274_20160930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_267_20150930_0_2026789x2039180">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-07</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_267_20150930_0_2026703x2350711">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:JulyTwoThousandAndElevenInvestorWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-07</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_267_20150930_0_2026703x2239968">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:AugustTwoThousandAndTenWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-07</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_267_20150930_0_2026703x2206022">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:TwoThousandAndThirteenRestructuringWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-07</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_267_20150930_0_2026703x2175516">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:ReimbursementNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-07</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_267_20150930_0_2026703x2169752">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:BridgeNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-07</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_267_20150930_0_2026703x2116523">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:ConvertibleNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-07</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_267_20150930_0_2026703x2108947">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:AmendedAndRestatedJuneTwoThousandAndTenWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-07</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_267_20150930_0_2021628x2039180">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-07</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_267_20150930_0_2021628x2025566">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-07</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_267_20150930_0_2021628x2022619">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-07</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_267_20150930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
    </entity>
    <period>
      <startDate>2015-01-07</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_1_20160930_0_2033594x2175516">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">emis:ReimbursementNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-09-30</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_1_20160930_0_2033594x2169752">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">emis:BridgeNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-09-30</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_1_20151026_0_2036820x2391453">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">emis:GLP1DevelopmentLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-10-26</startDate>
      <endDate>2015-10-26</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_1_20151026_0_2036820x2304402">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">emis:ExpansionLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-10-26</startDate>
      <endDate>2015-10-26</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_1_20151026_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
    </entity>
    <period>
      <startDate>2015-10-26</startDate>
      <endDate>2015-10-26</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_1_20151126_0_2033594x2175516">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">emis:ReimbursementNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-11-26</startDate>
      <endDate>2015-11-26</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_1_20151126_0_2033594x2031470">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-11-26</startDate>
      <endDate>2015-11-26</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_1_20140820_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
    </entity>
    <period>
      <startDate>2014-08-20</startDate>
      <endDate>2014-08-20</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20151231_0_2033594x2335086">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">emis:LoanAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20151231_0_2033594x2175516">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">emis:ReimbursementNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20151231_0_2033594x2169752">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">emis:BridgeNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20151231_0_2030037x2024220">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetsHeldUnderCapitalLeasesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20151231_0_2030037x2023509">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20151231_0_2027723x2116523">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">emis:ConvertibleNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20151231_0_2026789x2039180">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20151231_0_2026703x2364109">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:AugustTwoThousandAndTenMHRWaiverWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20151231_0_2026703x2352344">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:AmendedAndRestatedJulyTwoThousandAndElevenWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20151231_0_2026703x2350711">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:JulyTwoThousandAndElevenInvestorWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20151231_0_2026703x2291141">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:TwoThousandAndThirteenWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20151231_0_2026703x2239968">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:AugustTwoThousandAndTenWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20151231_0_2026703x2217977">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:AugustTwoThousandAndNineWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20151231_0_2026703x2206022">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:TwoThousandAndThirteenRestructuringWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20151231_0_2026703x2175516">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:ReimbursementNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20151231_0_2026703x2169752">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:BridgeNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20151231_0_2026703x2116523">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:ConvertibleNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20151231_0_2026703x2108947">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:AmendedAndRestatedJuneTwoThousandAndTenWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20151231_0_2026703x2097458">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:JulyTwoThousandAndElevenMHRWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20151231_0_2026703x2068720">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:JuneTwoThousandAndTenMHRWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20151231_0_2022410x2022419">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20151231_0_2022410x2021995">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20151231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20150106_0_2033594x2335086">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">emis:LoanAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-01-06</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20150106_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
    </entity>
    <period>
      <instant>2015-01-06</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20160930_0_2033594x2335086">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">emis:LoanAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20160930_0_2033594x2175516">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">emis:ReimbursementNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20160930_0_2033594x2169752">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">emis:BridgeNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20160930_0_2033594x2031470">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20160930_0_2030037x2024220">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetsHeldUnderCapitalLeasesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20160930_0_2030037x2023509">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20160930_0_2027749x2037322">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:RoyaltyArrangementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20160930_0_2027723x2116523">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">emis:ConvertibleNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20160930_0_2026789x2039180">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20160930_0_2026703x2364109">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:AugustTwoThousandAndTenMHRWaiverWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20160930_0_2026703x2352344">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:AmendedAndRestatedJulyTwoThousandAndElevenWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20160930_0_2026703x2291141">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:TwoThousandAndThirteenWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20160930_0_2026703x2239968">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:AugustTwoThousandAndTenWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20160930_0_2026703x2217977">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:AugustTwoThousandAndNineWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20160930_0_2026703x2206022">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:TwoThousandAndThirteenRestructuringWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20160930_0_2026703x2175516">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:ReimbursementNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20160930_0_2026703x2169752">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:BridgeNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20160930_0_2026703x2116523">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:ConvertibleNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20160930_0_2026703x2108947">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:AmendedAndRestatedJuneTwoThousandAndTenWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20160930_0_2026703x2097458">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:JulyTwoThousandAndElevenMHRWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20160930_0_2026703x2068720">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:JuneTwoThousandAndTenMHRWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20160930_0_2025588x2290570_2033594x2175516">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">emis:SecondAmendedAndRestatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">emis:ReimbursementNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20160930_0_2025588x2290570">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">emis:SecondAmendedAndRestatedMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20160930_0_2022410x2022419">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20160930_0_2022410x2021995">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20160930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
    </entity>
    <period>
      <instant>2016-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20150930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20121017_0_2033594x2169752">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">emis:BridgeNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-10-17</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20050926_0_2033594x2118616">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">emis:MHRPromissoryNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2005-09-26</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20050926_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
    </entity>
    <period>
      <instant>2005-09-26</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20150701_0_2028497x2033371">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-07-01</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20110712_0_2026703x2239968">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">emis:AugustTwoThousandAndTenWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-07-12</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20100608_0_2033594x2118616">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">emis:MHRPromissoryNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-06-08</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20150406_0_2033594x2335086">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">emis:LoanAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-04-06</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20161114_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
    </entity>
    <period>
      <instant>2016-11-14</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20141104_0_2033594x2335086">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">emis:LoanAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-11-04</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20140820_0_2033594x2335086">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">emis:LoanAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-08-20</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20140820_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
    </entity>
    <period>
      <instant>2014-08-20</instant>
    </period>
  </context>
  <context id="eol_PE5372----1610-Q0007_STD_0_20060516_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
    </entity>
    <period>
      <instant>2006-05-16</instant>
    </period>
  </context>
  <unit id="iso4217_USD_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="iso4217_USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="shares">
    <measure>shares</measure>
  </unit>
  <unit id="pure">
    <measure>pure</measure>
  </unit>
  <unit id="Borrowing">
    <measure>emis:Borrowing</measure>
  </unit>
</xbrl>